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I. INTRODUCTION 
Cancer is a major cause of morbidity and mortality worldwide. In 2008, more than 
7 million people died in consequence of their tumor burden1 and the incidence of 
cancer is even predicted to increase over the next few years.2, 3 There is a range of 
therapeutic options including conventional methods like surgery, chemotherapy 
and radiotherapy, but also immunotherapy, hormone therapy, hyperthermia and 
other supportive treatments. However, the unsatisfying cure rate and the occurring 
side effects of established treatment methods propel the research in cancer 
therapy. The aim is to improve common therapies, to combine them with more 
innovative therapeutics, and to evaluate novel medical techniques and drug 
technologies against cancer.  
Therefore, we investigated three promising anticancer approaches in vivo: specific 
and targeted polymer based siRNA therapy; novel nature-derived anticancer 
compounds; and polymer conjugated chemotherapeutics. Each of these 
therapeutic concepts generated promising in vitro results, before it was further 
evaluated in different mouse models. The experiments and results presented in 
this thesis have promise for further improvements in the fight against cancer. 
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1. Tumor targeted siRNA delivery 
1.1. Nucleic acid therapy 
Various diseases are caused by an alteration of the genetic material of single cells. 
In consequence, the encoded proteins can lose their functionality, entailing genetic 
diseases. Medicinal nucleic acids have been developed over the last decades4 in 
order to treat diseases caused by altered genes, like cardiovascular,5 neurological6 
and infectious7 disorders as well as cancer.8, 9 With these agents, genetically 
altered cells can be manipulated or cured through nucleic acid delivery. Thus, a 
mutated gene can be replaced or a new gene can be introduced by plasmid DNA 
(pDNA) or a gene can be silenced by RNA delivery or inactivated by antisense 
oligonucleotides. 
During the past 20 years, oligonucleotide and gene therapy has been strongly 
explored and many clinical trials, with a focus on cancer diseases, have been 
carried out.10 Within cancer therapy, the translation of messenger RNA (mRNA), 
responsible for tumor growth and metastasis or essential for cell survival, can be 
blocked. On the other hand, genes, encoding growth and migration hampering 
proteins, can be introduced or upregulated by affecting their opponent proteins. 
Gene therapy has already been successful, for example, in the treatment of 
patients with a blood-coagulation disorder (hemophilia B) or with a degenerative 
eye disease, called Leber congenital amaurosis (LCA).11, 12 However, the main 
difficulty in nucleic acid therapy and therefore, the reason for its still limited 
therapeutic use lies within the delivery of the nucleic acids.13 
1.2. siRNA therapy 
RNA delivery leads to a post transcriptional inhibition of gene expression by 
genetic interference.14 For this purpose, a specific double-stranded RNA (dsRNA) 
can be introduced into cells.15 In 2001, 21-nucleotide RNA duplexes, called small 
interfering RNA (siRNA), were identified as gene-specific therapeutics, which do 
not (or to a much lesser extent) induce inflammatory responses like long dsRNA 
does.16  
Nowadays, the single steps of RNA interference (RNAi) and the resulting gene 
silencing are very well explored.17 After entering the cell, the antisense strand of 
siRNA is incorporated by the so called RNA-induced silencing complex (RISC), 
whereas the sense strand is released and degraded.18 The antisense strand enables 
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RISC to identify the complementary mRNA, resulting in its cleavage by an 
activated RNase (Figure 1).19 Therefore, siRNAs can be used as a tool for 
sequence-specific knockdown and thus, they are a promising instrument in cancer 
therapy. 
In 2002, the therapeutic potential of siRNA was shown for the first time in an in 
vivo experiment.20 siRNA itself has an untargeted distribution, is rapidly degraded 
in the bloodstream21 and cleared by the kidneys.22 Additionally, the negative 
charge of siRNA hinders the crossing of cellular membranes. Therefore, safe 
delivery systems have to be developed for effective siRNA therapy.23 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mechanism of gene silencing by siRNA. In the cytosol, siRNA is 
incorporated into the RISC complex and the dsRNA is spliced into single strands. 
The sense strand is released and degraded. The antisense strand enables RISC to 
identify and cleave a complementary mRNA. The RISC-antisense strand complex 
remains stable during this process and can attach to a new corresponding mRNA. 
 
1.3. Obstacles in nucleic acid delivery 
To overcome the problems of oligonucleotide delivery and to enable the medical 
use of nucleic acids, various carriers have been investigated in recent years. 
Delivery systems have to overcome several extracellular and intracellular 
obstacles. In the extracellular environment, vectors have to protect the nucleic 
acids against degradation and must form stable complexes. After systemic 
injection, they need to shield the nucleic acids from interactions with diverse 
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blood components, for example albumin, erythrocytes, immune cells and 
enzymes. At the same time, the complexes have to circulate without being directly 
cleared by the kidneys or liver.24 The carrier system has to target specific cell 
types, like tumor cells, and overcome the cell membrane for being internalized. 
Intracellular, the complexes have to escape out of the endosome and the nucleic 
acid has to be released from the vector for being active in the cytoplasm or 
nucleus, in case of pDNA. Additionally, the carrier systems have to be non-toxic, 
non-immunogenic and non-pathogenic.25 
1.4. The range of delivery systems 
Carriers are primarily categorized into viral and synthetic vectors.26 Viruses can 
be utilized as nucleic acid transporters by replacing part of their genome with a 
therapeutic gene. They are very efficient delivery systems with the highest 
potency concerning gene transfection. Nevertheless, their therapeutic use is 
limited by several negative characteristics, especially their inflammatory, safety 
and immunogenic effects.27 The restricted payload capacity of viruses and the 
complexity of production are additional disadvantages.28 Therefore, the synthesis 
of non-viral vectors for oligonucleotide delivery is the main focus in this part of 
research. 
To benefit from the positive properties of both, viruses and synthetic vectors, 
virus-like carrier systems are investigated.29-31 The most promising artificial 
viruses are liposomes32 and polymers.28, 33 Liposomes are synthetic vesicles, 
consisting of a hydrophilic core enclosed in one or more lipid bilayers. Cationic 
polymers bind nucleic acids through electrostatic interactions with the negatively 
charged phosphate backbone. Polycations, like the gold standard linear 
polyethylenimine (LPEI),34 are commonly utilized in nucleic acid delivery. After 
endocytosis, these polyplexes reach the cytoplasm through endosomal disruption, 
caused by the so called proton sponge effect.35 These initial polyplexes bear 
several problems, like activation of the immune system36 and quick detection by 
the reticuloendothelial system.37 Additionally, they have toxic side effects caused 
by their molecular weight, as well as their cationic charge,38 and a lack of 
efficiency compared to viral vectors. The functionality and safety of polyplexes 
can be improved by adding several substructures for shielding, targeting and 
endosomal escape to the polymeric backbone.39 Figure 2 shows the critical 
delivery steps of such polyplexes. 
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Figure 2: Steps of siRNA delivery by shielded and targeted polyplexes. After 
systemic injection, polyplexes reach the tumor site through the leaky vasculature 
and their active targeting. By local application, polyplexes directly reach the 
extracellular environment of the tumor tissue. The targeting ligands bind to the 
appropriate receptors and lead to internalization of the polyplexes into the tumor 
cell. Polyplexes induce endosomal disruption and the siRNA is released into the 
cytosol and can be incorporated into the RISC complex. 
1.5. Precise multifunctional polycations 
The difficulty in polymer development is to build a carrier system, which is 
precise, highly efficient and can be reproducibly synthesized, and is at the same 
time multifunctional. It was a huge progress in precise vector synthesis, when 
Hartmann et al. designed defined polycationic structures and further on, libraries 
of polycations with clear structure-activity relationships were generated.40-42 The 
functionality of these polymers was improved by the work of Dohmen et al., 
adding several substructures to the polycationic backbone or the siRNA itself. 
Figure 3 shows the synthesized polymer under investigation in the current thesis. 
 
 
 
 
Figure 3: Folic acid targeted defined polymer. FolA-PEG24-K(Stp4-C)2. 
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The synthesis was based on a linear backbone consisting of polyamino-amides, 
using Stp (16-amino-4-oxo-5,8,11,14-tetraaza-hexadecanoic acid) as building 
block.41 Cysteines were incorporated to increase polyplex stability by disulfide 
formation. For shielding, and therefore preventing unwanted interactions of the 
polyplexes in the body, polyethylene glycol (PEG) was attached by means of a 
branching lysine. To target the synthesized vectors to folate receptor 
overexpressing tumor cells, folic acid was incorporated as target ligand. The 
endosomolytic domain Inf7,43 which is highly lytic at endosomal pH, was 
covalently bound to the siRNA itself to ensure the endosomal escape of the 
polyplexes. These modifications led to nano sized multifunctional polyplexes for 
receptor mediated siRNA delivery.44  
2. Myxobacterial compounds as natural anticancer drugs 
2.1. Natural products as pharmaceutical compounds 
Natural products play an important role in drug discovery and have been the 
origin of more than 80% of therapeutic drugs in former times.45, 46 Despite the 
increase of alternative drug discovery methods nowadays, natural products are 
still of particular importance and are basis for every second approved drug since 
1994.47 
They are used for the production of various pharmaceuticals, in particular of 
anticancer and anti-infective drugs like doxorubicin, paclitaxel and penicillin.48 
The benefits of natural compounds are their broad therapeutic effects, their 
diversity of chemical structures and their increased absorption compared to 
synthetic drugs. The disadvantages are among other things, the difficulty of a 
continuous supply and their chemical complexity.47 
Natural products derive from animals, plants or microbial sources. Within 
microbes, fungi and terrestrial actinomycetes are the best-studied source, 
producing a wide range of secondary metabolites.49 However, looking for novel 
natural products, various microbes are investigated in recent decades with a 
growing interest in cyanobacteria,50 marine actinomycetes51, 52 and 
myxobacteria.53 
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2.2. Myxobacteria and their bioactive secondary metabolites 
Myxobacteria are gram-negative bacteria and belong to the delta group of 
proteobacteria. These microbes are able to live in various habitats including the 
sea,54, 55 but are mainly residing in soil.56, 57 Myxobacteria have special 
characteristics, like the ability to move actively by gliding on a surface58 and to 
form multicellular fruiting bodies, when resources are becoming scarce.59 Another 
remarkable characteristic is the production of a wide range of secondary 
metabolites, which are well explored these days.53 
In 1947, it was first described that myxobacteria have an antibiotic activity.60 
Thirty years later, in 1977, the first secondary metabolite, ambruticin, was isolated 
from a myxobacterium.61 Through the work of Reichenbach and Hoefle, 
myxobacteria have gained increasing attention during the last two decades as 
producers of several biological active secondary metabolites.62 These products 
often have unusual structural elements and target cell structures, which are rarely 
or not targeted by other metabolites.63 Therefore, they often own a complete novel 
mode of action.64 There need to be further investigations on why myxobacteria 
produce this range of secondary metabolites, but it is assumed that they protect 
their habitat in the highly competitive terrestrial environment.65 
To date, there are more than 60 families of myxobacterial compounds identified.64 
Besides their antifungal (54%) and antibacterial (29%) bioactivity, myxobacterial 
metabolites are also cytotoxic towards mammalian cells.66 Therefore, 
myxobacterial products are of great interest in cancer therapy. 
They are the research topic of the DFG network FOR 1406 (Prof. Vollmar/Prof. 
Müller "Exploiting the Potential of Natural Compounds: Myxobacteria as Source 
for Leads, Tools, and Therapeutics in Cancer Research”) to which our lab (Prof. 
Wagner) contributes. 
Most of the reported cytostatic metabolites of myxobacteria interact with the 
eukaryotic cytoskeleton. They can promote (e.g. epothilone67) or inhibit (e.g. 
tubulysin68) tubulin polymerization or interfere with actin polymerization (e.g. 
chondramide69). Other compounds, for example apicularen or archazolid, are 
cytotoxic, as they inhibit vacuolar ATPases (V-ATPases) of mammalian cells.70, 71 
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2.2.1. Archazolid 
Archazolid (Figure 4) is a macrolactone, isolated from the myxobacteria 
Archangium gephyra and Cystobacter violaceus.71  
 
 
 
 
 
 
 
Figure 4: Chemical structure of archazolid A and B. Archazolid A, R = CH3; 
archazolid B, R = H. 
Archazolid targets V-ATPases of eukaryotic cells. These ATP-dependent proton 
pumps are ubiquitous in endomembranes and often occur in cell plasma 
membranes. They regulate the proton concentration in the intracellular acidic 
compartments and the cytoplasm of diverse cells. V-ATPases consist of a 
membrane bound V0 domain for proton translocation and a catalytic V1 domain 
that is directed towards the cytosol.72 Beside cytoplasmic pH homeostasis, V-
ATPases are involved in various cellular processes, including receptor mediated 
endocytosis and intracellular transport.73 
Additional to their normal incidence, these proton pumps are overexpressed 
within the plasma membrane of various malignant tumor types, acidifying the 
extracellular space.74 Several tumor cells degrade the extracellular matrix through 
the secretion of lysosomal enzymes. These enzymes have a significant higher 
activity in an acidic environment. Therefore, the V-ATPase is suspected to be 
involved in tumor invasiveness and migration.73, 75 
Before archazolid was identified, potent V-ATPase inhibitors like the 
plecomacrolides bafilomycin and concanamycin were already discovered in the 
early eighties.76-78 Archazolid inhibits V-ATPases very specific and effective with 
IC50 values in the low nanomolar range.72 Its efficacy is comparable to the 
efficacy of these two well established compounds named above.  
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In vitro, archazolid impairs as well tumor cell proliferation as tumor cell 
migration through the inhibition of V-ATPases.79, 80 These results are promising 
for further in vivo investigations of this myxobacterial compound. 
2.2.2. Pretubulysin 
Pretubulysin (Figure 5) is a precursor of the myxobacterial product tubulysin, 
which is produced by Archangium gephyra and Angiococcus disciformis.49  
 
 
 
 
 
Figure 5: Chemical structure of pretubulysin.
 
 
Tubulysins are a family of nine myxobacterial products that interact with the 
eukaryotic cytoskeleton. 
The yield of the synthetic production of pretubulysin is higher compared to 
tubulysin, as it has a less complex structure. This reduces the supply problems, 
which are typical for natural compounds due to their high chemical complexity. 
Fortunately, despite this structural simplification, pretubulysin loses only little 
efficacy in the inhibition of cell proliferation and migration compared to tubulysin 
and still has a subnanomolar activity.81 
The cytotoxicity of pretubulysin is based on the inhibition of the polymerization 
of tubulin to microtubules.82 Microtubules form the spindle apparatus and are 
therefore essential for the separation of chromosomes during mitosis. Besides 
mitosis, microtubules are also necessary for intracellular transports and cell 
movements. Thus, hampering tubulin polymerization leads to a reduction of cell 
proliferation and migration. 
Compared to other tubulin interfering natural compounds, like epothilones and 
taxol, tubulysins even have a 20- till 100-fold higher efficacy on hampering cell 
growth.81 Epothilones have already been demonstrated to be effective in vivo 
against multidrug resistant tumors.83 In 2012, the Vollmar group together with our 
group (Rath et al.) first proved the efficacy of pretubulysin concerning tumor 
growth inhibition in a murine HuH7 tumor model.84 
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2.2.3. Chondramide 
Chondramides (Figure 6) are peptides, produced by the myxobacteria 
Chondromyces crocatus.69  
 
 
 
 
 
 
 
Figure 6: Chemical structure of chondramide. Chondramide A, R1 = OMe, R2 
= H; chondramide B, R1 = OMe, R2 = Cl; chondramide C, R1 = H, R2 = H; 
chondramide D, R1 = H, R2 = Cl. 
 
These peptides induce the polymerization of the multi-functional protein actin. 
Actin polymerization and depolymerization is not only necessary for the process 
of chemotaxis, but also for cytokinesis. Interfering with these procedures leads to 
a dysfunction in cell migration and proliferation. After epothilone85 and 
rhizopodin,86, 87 the chondramides had been the third class of myxobacterial 
metabolites that interfere with the cytoskeleton of eukaryotic cells.88 
Closer related are the chondramides to jasplakinolide, a natural compound, 
isolated from marine sponges of the genus Jaspis89 that induces actin 
polymerization. Already years ago, chondramide was identified to reduce cell 
growth of different cell lines in vitro.69 Sasse et al. compared the efficacy of 
chondramide and jasplakinolide on cell growth inhibition and showed that the 
IC50 values of these two compounds are relatively similar and in the nanomolar 
range.88 As jasplakinolides have already shown to hamper tumor metastasis in 
animal experiments,90 this could be a hint that chondramide has an in vivo 
anticancer efficacy as well. 
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3. Polymer formulations of chemotherapeutics 
3.1. The drawbacks of chemotherapeutics 
Cytostatic drugs play an important role in cancer therapy, but their clinical use is 
still limited. Conventional chemotherapeutics distribute randomly in the body 
when injected systemically and have poor tumor selectivity. This leads to a low 
therapeutic efficacy and strong toxic side effects, restricting their application and 
preventing an increase in cancer cure rate in recent years.91, 92 The underlying 
cause is that most cytostatic drugs, being low-molecular-weight substances, are 
able to diffuse out of the blood circulation into any tissue, where they hamper cell 
division (mitosis). Fast dividing cells of the bone marrow, the digestive tract and 
hair follicle are especially affected besides tumor cells, leading to typical toxicity 
like myelosuppression, mucositis and hair loss. For a safe and more effective 
application, chemotherapeutics need to be guided to the tumor tissue. Besides 
active targeting, anticancer drugs can be targeted passively93, 94 through the 
attachment to a polymeric carrier. Consequently, the molecular weight of the drug 
is increased and the pharmacokinetics change radically.95 This enables tumor-
specific targeting and reduces the access to healthy tissue due to the “enhanced 
permeability and retention” (EPR) effect.96 
Another obstacle, limiting the efficacy of chemotherapy, is the development of 
chemoresistance. Resistance to anticancer drugs can be intrinsic and exist before 
the treatment, or tumors can become resistant during chemotherapeutic 
application. When resistance is acquired, tumors may become resistant not only to 
the currently used drug, but also to other therapeutics with different modes of 
action.97 There are diverse mechanisms of drug resistance, including active efflux 
of chemotherapeutics out of the tumor cell through ABC transporters, alteration of 
drug-target interaction and changes in cellular response like increased DNA repair 
mechanisms, tolerating stress conditions and defects in apoptotic pathways. 98-100 
An individual tumor can use one or more of these mechanisms against 
chemotherapeutics, making their administration ineffective. It is believed that 
chemoresistance is responsible for about 90% of therapeutic failure in metastatic 
cancer treatment.97 
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3.2. EPR effect 
In 1986 Matsumura and Maeda first reported the EPR effect (Figure 7).101 
 
Figure 7: Passive tumor targeting due to the EPR effect. Small molecules are 
able to diffuse out of the blood circulation into any tissue. Macromolecules 
however, can only pass leaky tumor endothelium, missing the ability to diffuse 
through normal endothelial cells. Reaching the tumor, macromolecules 
accumulate and remain in this tissue, as tumors have an impaired lymphatic 
drainage. 
 
This effect is based on a special morphology of tumor vessels. As tumors are 
rapidly growing, they need an increased amount of nutrients and oxygen. To 
ensure a sufficient supply, tumors possess several pathophysiological 
characteristics, like intense angiogenesis,102, 103 hypervasculature with defective, 
leaky vessels and a reduced lymphatic drainage.104 These characteristics enable 
macromolecules to reach the tumor site through leaky vessels and accumulate in 
the tumor tissue due to the impaired lymphatic drainage. As macromolecules are 
unable to penetrate through tight endothelial junctions of normal vessels and are 
not rapidly cleared by the kidneys due to their large size, these tumor 
characteristics can be used for passive tumor targeting.105, 106 Small molecules in 
contrast, pass through the endothelium of normal blood vessels into any tissue. 
This leads to an unspecific body distribution and a short plasma half-life due to 
fast renal clearance. 
To benefit from the EPR effect, low-molecular-weight anticancer drugs are 
conjugated to polymers, enhancing the efficacy of the drugs and decreasing their 
side effects. Additionally, the polymeric conjugation reduces the renal clearance 
and prolongs the circulation time, which plays an important role for passive drug 
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targeting.107, 108 Thus, the drug concentration in the tumor tissue can reach a 
10-30 times higher level than in the blood circulation. 
Since its first description, the EPR effect is basis for modifications of diverse 
anticancer therapeutics,109-111 including several drugs that are already evaluated in 
clinical trials.112, 113  
3.3. Polymer-anticancer drug conjugates 
The term polymer therapeutics114 includes polymeric drugs, polyplexes, polymeric 
mycelles, polymer-protein conjugates and polymer-drug conjugates.112 Thereby, 
the polymer has always the function of guiding its binding partner to its 
therapeutic target. 
Ringsdorf first described polymer-anticancer drug conjugates in 1975.115 These 
conjugates always include a water soluble polymeric carrier, a biodegradable 
linker and an antitumor drug.116 The polymeric conjugation enhances the 
solubility of hydrophobic drugs117 and improves their pharmacokinetic 
characteristics.118 The circulation time is prolonged, the clearance hampered and 
the drug passively targeted to the tumor tissue through the EPR effect. 
Additionally, the polymer can protect the drug against degradation119 and can 
overcome multidrug resistance (MDR), as macromolecules can accumulate in 
tumor cells without being recognized by the permeability glycoprotein 
(P-glycoprotein), one of the main mediators of multidrug resistance.120 
To ensure an improvement of the drugs’ efficacy, polymers need to meet several 
requirements. They have to be non-toxic, non-immunogenic and to carry an 
appropriate drug payload, bound over a stable linker that releases the drug at the 
target are. In addition, their molecular weight has to be high enough to enable a 
long circulation time.121 If these prerequisites are fulfilled, an active targeting 
ligand can be introduced122, 123 but is not absolutely necessary. 
Since the first synthetic polymer-anticancer conjugate entered clinical trial in 
1994,116 several more have followed.124-126 Anticancer conjugates, containing for 
example doxorubicin,127 paclitaxel128 or camptothecin,129 are the most investigated 
conjugates in clinical trials.130 Despite this fact, none of these structures is on the 
market until now. 
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3.4. Polymer-melphalan conjugates 
Chemotherapy formerly started with the discovery of the cytotoxic effect of 
nitrogen mustards at Yale in 1942.131 Nitrogen mustards, including the 
chemotherapeutic melphalan hydrochloride, are nonspecific DNA alkylating 
agents. Melphalan was first introduced more than 50 years ago and has a wide 
spectrum of antitumor activity.132, 133 It is used for the treatment of various tumors, 
but bears several disadvantages, like nonspecific distribution, low bioavailability, 
drug resistance and side effects including bone marrow suppression, vomiting and 
hair loss. The first synthesized polymer-drug conjugates already contained, among 
some other drugs, melphalan. Since then, various melphalan conjugates have been 
developed.134, 135 
Polymers with repeating phosphoester in the backbone are highly biocompatible 
and similar to bio-macromolecules such as nucleic acids, and therefore popular in 
polymeric conjugate synthesis.136-138 Thus, melphalan was covalently or non-
covalently bound to three biodegradable and water soluble polyphosphoesters 
(Figure 8 - Figure 10) for the current study. In Conjugate 1, melphalan was 
covalently immobilized by reacting with poly(oxyethylene H-phosphonate). 
Complex 2 consisted of electrostatic complexes of negatively charged 
polyphosphodiester poly(hydroxyoxyethylene phosphate) and positively charged 
protonated melphalan. In Complex 3, melphalan was hydrogen-bonded to the 
polyphosphotriester poly(methyloxyethylene phosphate). 
Figure 8: Conversion of polyphosphonate and melphalan into Conjugate 1 
(formation of P-N and P-O covalent bonds). 
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Figure 9: Salt formation of melphalan hydrochloride with polyphosphodiester 
into ionic Complex 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Immobilization of melphalan hydrochloride with polyphosphotriester 
into hydrogen-bonded Complex 3. 
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4. Aims of the thesis 
4.1. siRNA delivery 
The aim of this part of the thesis was to analyze the synthesized and in vitro tested 
multifunctional polycations described above (Figure 3) in different in vivo trials 
and to improve them for being more efficient in animal experiments. Evaluation 
of the polymers should be done in combination with fluorescent (Cy7-) labeled 
siRNA and with Inf7 conjugated siRNA. The aim was, to analyze the 
functionality of the targeted carrier, investigating the cell attachment and 
internalization of the polyplexes and the siRNA’s silencing effect in vivo. In the 
next step it was purposed to analyze and, if applicable, to improve the 
characteristics of the polyplexes after intravenous injection to achieve a well-
tolerated, function nucleic acid therapy method for in vivo assays. 
4.2. Myxobacterial compounds 
Each of the three myxobacterial compound families archazolid, pretubulysin and 
chondramide is cytotoxic towards mammalian cells. It has been shown that they 
inhibit tumor cell proliferation and migration in different in vitro assays.  
In vivo however, only pretubulysin had been analyzed before concerning its effect 
on tumor angiogenesis and tumor growth, but not on tumor metastasis. About 
archazolid and chondramide, there were no in vivo data published at all. 
Therefore, one aim of this study as subproject of the FOR 1406 network was, to 
continue the evaluation of these compounds and to investigate if these secondary 
metabolites have the potential to hamper tumor growth and tumor metastasis in 
vivo. Additionally, we aimed to gather important information about the toxicity of 
the compounds after systemic injection. 
4.3. Polymer-melphalan formulations 
Within this thesis, the three novel polymeric analogues of melphalan first had to 
be analyzed concerning their effects on cell proliferation and viability. The 
polymer-melphalan conjugate, if effective, was subsequently to be evaluated in 
two animal experiments. The aim was to improve the antitumoral efficacy of pure 
melphalan especially in vivo by its polymeric immobilization, taking advantage of 
the typical characteristics of polymer-drug conjugates. These include an improved 
solubility and possibly the protection of the drug against degradation, as well as a 
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reduction of chemoresistance, a delayed release of the conjugated drug and the 
benefit of the EPR effect. 
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II. MICE, MATERIALS AND METHODS 
1. Mice 
1.1. Strains 
1.1.1. NMRI nude mice 
Female Rj:NMRI-Foxn1nu/Foxn1nu mice (Janvier, Le Genest-St-Isle, France) 
belong to a mutant strain, which has its origin in an outbred colony of albino 
mice. These animals lack a thymus, are unable to produce T cells, and therefore 
are immunodeficient. Thus, they were used for xenograft tumor models. 
1.1.2. BALB/c mice 
Female BALB/cByJRj mice belong to an inbred strain and were purchased from 
Janvier, Le Genest-St-Isle, France. These albino mice have a competent immune 
system and thus, were used in a syngeneic tumor model.  
1.1.3. SCID mice 
Female SCID mice (CB17/Icr-Prkdcscid/IcrCrl) were purchased from Charles 
River. These mice have a severe combined immunodeficiency involving B and T 
lymphocytes. Therefore, they were used for xenograft tumor models. 
1.2. Housing 
Mice were housed under specific pathogen-free conditions in individually 
ventilated cages (IVC type II long). They were kept within a 12 h day/night cycle, 
with food and water ad libitum. Mice were purchased with an age of five weeks 
and experiments were started after one week of acclimatization. All animal 
experiments were performed according to the guidelines of the German law for 
protection of animal life and approved by the local ethics committee. 
2. Materials 
2.1. Cell culture 
KB cells ATCC (Wesel, Germany) 
4T1-Luc cells Caliper (Alamenda, CA, USA) 
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SKBR3 cells ATCC (Wesel, Germany) 
U87MG cells ATCC (Wesel, Germany) 
HuH7 cells HSRRB (Tokyo, Japan) 
RPMI 1640 medium Invitrogen (Karlsruhe, Germany) 
Ham’s F12 medium Invitrogen (Karlsruhe, Germany) 
DMEM medium Invitrogen (Karlsruhe, Germany) 
FCS (fetal calf serum) Invitrogen (Karlsruhe, Germany) 
TE (Tris, EDTA) Biochrom (Berlin, Germany) 
PBS (phosphate buffered saline) Biochrom (Berlin, Germany) 
Cell culture plates, flasks TPP (Trasadingen, Switzerland) 
Penicillin-Streptomycin Biochrom (Berlin, Germany) 
L-alanyl-L-glutamine Biochrom (Berlin, Germany) 
2.2. In vitro experiments 
MTT bromide Sigma-Aldrich (Steinheim, Germany) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (Steinheim, Germany) 
Trypsin Biochrom (Berlin, Germany) 
EDTA Sigma-Aldrich (Steinheim, Germany) 
Hoechst 33342 Sigma-Aldrich (Steinheim, Germany) 
Boric acid Sigma-Aldrich (Steinheim, Germany) 
Trisma® Base Sigma-Aldrich (Steinheim, Germany) 
GelRed Biotium Inc. (Hayward, USA) 
TCEP = Tris(2-carboxyethyl) 
phosphine 
Sigma-Aldrich (Steinheim, Germany) 
Glycerine Sigma-Aldrich (Steinheim, Germany) 
Xylene cyanol Sigma-Aldrich (Steinheim, Germany) 
Hepes Biomol (Hamburg, Germany) 
LabTek chamber slide NUNC (Wiesbaden, Germany) 
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2.3. In vivo experiments 
Luciferin Promega (Mannheim, Germany) 
Forene® Abbott GmbH & Co. KG  
(Wiesbaden, Germany) 
Bepanthen® Bayer Vital GmbH (Leverkusen, Germany) 
Syringes, needles BD Consumer Healtcare 
(Heidelberg, Germany) 
2.4. Ex vivo experiments 
Mayer’s haematoxylin solution Sigma-Aldrich (Steinheim, Germany) 
Eosin Y Sigma-Aldrich (Steinheim, Germany) 
Tissue-Tek® Cryomold Sakura Finetek (Heppenheim, Germany) 
Tissue-Tek® O.C.T. Compound Sakura Finetek (Heppenheim, Germany) 
Tissue-Tek® Mega-Casette Sakura Finetek (Heppenheim, Germany) 
Superfrost ultraplus® Menzel GmbH (Braunschweig, Germany) 
DAPI Sigma-Aldrich (Steinheim, Germany) 
Heparin (25.000 I.E./5mL) Ratiopharm GmbH (Ulm, Germany) 
2.5. Instruments 
Luminometer Centro LB 960 Berthold Technologies 
(Bad Wildbad, Germany) 
IVIS Lumina Caliper Life Science (Rüsselsheim, Germany) 
Shaver Aesculap Suhl GmbH (Suhl, Germany) 
DIGI-MET Calliper Preisser (Gammertingen, Germany) 
LSM 510 Meta Zeiss (Jena, Germany) 
Olympus BX41 Olympus (Hamburg, Germany) 
Leica CM3050 S Leica Microtechnologies 
(Bensheim, Germany) 
Leica EG1150 H Leica Microtechnologies 
(Bensheim, Germany) 
Leica RM2265 Leica Microtechnologies 
(Bensheim, Germany) 
Axiovert 200 Zeiss (Jena, Germany) 
Plate reader Tecan (Groedig, Austria) 
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2.6. Software 
Graph Pad Prism 5 software Graph Pad Software (San Diego, USA) 
Living Image 3.2 Caliper Life Science (Rüsselsheim, Germany) 
2.7. siRNA 
siCtrl Axolabs 
(formerly Roche Kulmbach, Germany) 
AuGuAuuGGccuGuAuuAG dTsdT 
CuAAuAcAGGCcAAuAcAU dTsdT 
siEG5 Axolabs 
(formerly Roche Kulmbach, Germany) 
ucGAGAAucuAAAcuAAcu dTsdT 
AGUuAGUUuAGAUUCUCGA dTsdT 
siAHA1-Cy7 Axolabs 
(formerly Roche Kulmbach, Germany) 
GGAuGAAGuGGAGAuuAGu dTsdT 
(Cy7)(NHC6)ACuAAUCUCcACUUcAUCC 
dTsdT 
Capital letters refer to standard RNA ribonucleotides; small letters (u, c) refer to 
2’-O-methyl-ribonucleotides; dT refers to DNA building block deoxy-thymidine; 
s refers to stabilizing phosphorothioate linkage. 
2.8. Peptides 
Inf 7 (influenza HA2 – derived) Biosyntan (Berlin, Germany) 
2.9. Polycations 
Polycations were synthesized by Dr. Christian Dohmen (PhD thesis 2012, LMU). 
FolA-PEG24-K(Stp4-C)2  
FolA-PEG48-K(Stp4-C)2  
FolA-PEG72-K(Stp4-C)2 
A-PEG120-K(Stp4-C)2  
A-PEG192-K(Stp4-C)2 
C-Y3-Stp4-K(Stp4-Y3-C)-PEG24-FolA 
C-K(K-CapA2)-Stp4-K(Stp4-K(K-CapA2)-C)-PEG24-FolA 
C-K(K-SteA2)-Stp4-K(Stp4-K(K-SteA2)-C)-PEG24-FolA 
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2.10. Polyphosphoesters 
Polyphosphoesters and melphalan formulations were synthesized by Dr. Anita 
Bogomilova (LMU guest scientist 2011). 
poly(oxyethylene H-phosphonate)  
poly(hydroxyoxyethylene phosphate)  
poly(methyloxyethylene phosphate)  
2.11. Myxobacterial compounds/melphalan 
Archazolid A Helmholtz-Institut für Pharmazeutische Forschung 
Saarland (Prof. Rolf Müller) 
Pretubulysin Helmholtz-Institut für Pharmazeutische Forschung 
Saarland (Prof. Rolf Müller) 
Chondramide B Helmholtz-Institut für Pharmazeutische Forschung 
Saarland (Prof. Rolf Müller) 
Melphalan hydrochloride Sigma-Aldrich (Steinheim, Germany) 
3. Methods 
3.1. Cell culture  
KB (human cervix carcinoma), SKBR3 (human breast adenocarcinoma) and 4T1-
Luc (luciferase expressing murine breast adenocarcinoma) cells were grown in 
RPMI 1640 medium. U87MG (human glioblastoma-astrocytoma) cells were 
cultured in DMEM, HuH7 (human hepatocellular carcinoma) cells were cultured 
in DMEM/Ham’s F12. All media were supplemented with 10% FCS and 4 mM 
stable glutamine. 1% penicillin-streptomycin was supplemented to the medium for 
cells cultured for in vitro assays.  
3.2. Cell viability assay 
HuH7, SKBR3 and U87MG cells were seeded into 96 well plates (1x104 
cells/well). After 24 h, culture medium was replaced with 80 µL fresh growth 
medium containing 10% FCS and cells were treated with 20 µL of several 
dilutions of the novel formulations, equivalent concentration of pure melphalan or 
with the polymeric carriers alone. A 20 µL buffer solution was used as control. 
After 48 h, 10 µL/well MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) were added with a final concentration of 
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0.5 mg/mL. After 1 h of incubation, unreacted dye and medium were removed. 
Plates were frozen at -80 °C. After defrosting, 200 µL dimethyl sulfoxide were 
added to each well and the purple formazan product was quantified by a plate 
reader at 590 nm with background correction at 630 nm. The relative cell viability 
(%) relative to control wells was calculated by [A] test / [A] control × 100. 
3.3. Proliferation assay 
HuH7, SKBR3 and U87MG cells were seeded into 96 well plates 
(1x104 cells/well). After 24 h, culture medium was replaced with 80 µL fresh 
growth medium containing 10% FCS and cells were treated with 20 µL of several 
dilutions of the novel conjugates, equivalent concentration of pure melphalan or 
with the polymeric carriers alone. 20 µL buffer was used as control. After 48 h, 
cells were washed with 200 µL PBS per well and 40 µL trypsin/EDTA-solution 
was added into each well. Plates were frozen at -80 °C. After defrosting, 200 µL 
Tris-NaCl-EDTA-buffer and the DNA stain H33342 (final concentration: 
1 µg/mL) were added per well. After 15 min of incubation without light 
irradiation, 200 µL of the solutions were pipetted onto a 96 well multititer plate. 
Fluorescence was measured by a plate reader and the relative cell proliferation 
(%) was calculated relative to control wells by [A] test / [A] control × 100. 
3.4. Gel electrophoresis of polyplexes 
A 2.5% agarose gel was prepared by dissolving agarose in TBE buffer (trizma 
base 10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 L of water) and 
boiling everything up to 100 °C. After cooling down to about 50 °C and addition 
of GelRed, the agarose gel was casted in the electrophoresis unit. Polyplexes 
containing 500 ng of siRNA in 20 µl HBG and loading buffer (prepared from 
6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g xylene cyanol) 
were placed into the sample pockets. Electrophoresis was performed at 120 V for 
40 min. 
3.5. Fluorescence correlation spectroscopy (FCS) 
The particle size of polyplexes was measured by fluorescence correlation 
spectroscopy using an Axiovert 200 microscope with a ConfoCor2 unit. 
A HeNe laser (633 nm, average power of 50 µW at the sample) was used for 
excitation. The objective was a 40x (NA = 1.2) water immersion apochromat. 
Particles were formed in a volume of 10 µL of HEPES with a final concentration 
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of 14.8 µM Inf7-siRNA, including 50 nM Cy5-labeled Inf7-siRNA at indicated 
N/P ratios. After polyplex formation, the particles were filled up with 200 µL of 
HEPES and transferred to eight-well LabTek I chamber slides for measurement. 
Three experimental replicates were measured. 
3.6. In vivo experiments 
For intravenous applications, injection volumes did not exceed 250 µL. 
Intratumoral injections were performed, using 50 µL of the solutions. All siRNA 
experiments were carried out with 50 µg siRNA per injection and with an N/P of 
16. 
3.6.1. Intratumoral polyplex retention 
KB cells (5x106 per mouse) were injected subcutaneously in 150 µL PBS into the 
nape of 15 anesthetized NMRI nude mice. Anesthesia was performed with 3% 
isoflurane in oxygen. On day eleven after tumor inoculation, mice were divided 
into three groups and anesthetized with isoflurane. Targeted (FolA-PEG24-K(Stp4-
C)2) and untargeted (A-PEG24-K(Stp4-C)2) polyplexes, containing 50 µg Cy7-
labeled siRNA, or pure Cy7-labeled siRNA, were injected intratumorally in 50 µL 
HBG. Near infrared (NIR) imaging was performed with a CCD camera 0 h, 4 h, 
24 h, 48 h, 72 h, 96 h and 120 h after injection. For evaluation of the images, the 
efficiency of the fluorescence signals was analyzed. The efficiency number for 
each pixel stands for the fraction of fluorescent photons relative to each incident 
excitation photon. For image interpretation, color bar scales were equalized, using 
a minimum of 4.7e-7 and a maximum of 1.0e-5 fluorescent photons/incident 
excitation photon. For quantification of the tumor retention of the polyplexes, 
Regions of Interest (ROIs) were defined and total signals per ROI were calculated 
as total efficiency/area with Living Image software 3.2. The average signal 
intensities per group were compared over time (mean ± S.E.M. of five mice per 
group). Pictures were taken with an exposure time of 5 s and medium binning. 
3.6.2. Intratumoral EG5 gene silencing after local polyplex application 
KB cells (5x106 per mouse) were injected in 150 µL PBS subcutaneously into the 
nape of twelve anesthetized NMRI nude mice. On day eleven after tumor 
inoculation, mice were divided into two groups. Mice were anesthetized with 3% 
isoflurane in oxygen. FolA-PEG24-K(Stp4-C)2 combined with 50 µg Inf7-siEG5 or 
with 50 µg Inf7-siCtrl was injected intratumorally. After 24 h, mice were 
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euthanized by cervical dislocation and tumors were harvested. Tumors were fixed 
in formalin and embedded into paraffin. Tumors were cut with a microtome into 
4.5 µm slices and stained with hematoxylin (2 min) and eosin (5 min). Results 
were evaluated and documented, using an Olympus BX41 microscope. 
3.6.3. Systemic distribution of the initial and modified polyplexes 
KB cells (5x106 per mouse) were injected in 150 µL PBS subcutaneously into the 
nape of anesthetized NMRI nude mice. Anesthesia was performed with 3% 
isoflurane in oxygen. On day 13 after tumor inoculation, the initial folate targeted 
polyplex, polyplexes with extended PEG spacers (2 PEG, 3 PEG) or with 
hydrophobic modifications (tyrosine, caprylic acid, stearyl acid) containing Cy7-
labeled siRNA, were injected intravenously in 250 µL HBG. Untargeted 
polyplexes with 5 PEG or 8 PEG chains were injected into tumor free NMRI nude 
mice. Each polymer was injected intravenously into three animals, with only one 
exception. The stearyl acid containing polyplexes were only injected in one 
mouse, as this mouse died after the application. 
NIR fluorescence measurement was started immediately after polyplex injection 
and repeated after 0.25 h, 1 h, 4 h and 24 h (polyplexes with 1 PEG, 2 PEG, 
3 PEG, tyrosine, caprylic acid or stearyl acid) or after 0.25 h, 0.5 h and 1 h 
(polyplexes with 5 PEG and 8 PEG). For evaluation, the efficiency of the 
fluorescence signals was presented, using equalized color bar scales for each 
group. Pictures were taken with an exposure time of 5 s and medium binning. 
3.6.4. Intratumoral EG5 gene silencing after systemic polyplex 
application 
KB cells (5x106 per mouse) were injected in 150 µL PBS subcutaneously into the 
nape of 18 anesthetized NMRI nude mice. Anesthesia was performed with 3% 
isoflurane in oxygen. On day 13, mice were treated i.v. with FolA-PEG24-K(Stp4-
C)2 containing Inf7-siEG5, FolA-PEG24-K(Stp4-C)2 containing Inf7-siCtrl or A-
PEG24-K(Stp4-C)2 containing Inf7-siEG5 on two consecutive days. 24 hours after 
the last injection, mice were euthanized through cervical dislocation. Tumors were 
harvested, embedded into Tissue-Tek and stored at -20°C. The following day, 
tumors were cut into 5 µm slices, using a cryotom. Afterwards, they were dried, 
fixed with paraformaldehyde and stained with DAPI. Results were interpreted and 
documented with a Zeiss Axiovert 200 fluorescence microscope. 
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3.6.5. Gel electrophoresis of urine samples  
Tumor free NMRI nude mice were treated intravenously with FolA-PEG24-
K(Stp4-C)2 containing Cy7-labeled siRNA (n = 2), FolA-PEG72-K(Stp4-C)2 
containing Cy7-labeled siRNA (n = 2) or pure Inf-siEG5 (n = 1). At 4 h after 
application, mice were anesthetized with 3% isoflurane in oxygen and placed in 
dorsal position. Bladders were blindly punctured with an insulin syringe. Urine 
samples were analyzed in a 2.0% (w/v) agarose gel in TBE buffer (800 mM Tris, 
3.8 M boric acid, 2 mM EDTA) without further dilution. For staining, GelRed 
was added to the liquid gel. Where indicated, 2 µL of a 0.5 M TCEP solution and 
2 µL of a heparin solution were added. Gel electrophoresis was performed using 
an electric tension of 80 V for 60 min. 
3.6.6. Effect of myxobacterial compounds on tumor colonization 
In the colonization experiments with archazolid A, 20 BALB/c mice were divided 
into two groups (treatment and control) and inoculated with 1 x 105 4T1-Luc cells 
(stably transfected with the luciferase gene) via the tail vein. 24 h and 4 h before 
tumor cell injection, the treatment group was premedicated intravenously with 
1 mg/kg archazolid A in 5% DMSO/PBS. On day eight after tumor cell 
inoculation, mice were anesthetized with 2% isoflurane in oxygen and 6 mg Na-
luciferin were injected intraperitoneally. 15 min later, bioluminescence imaging of 
the still anesthetized mice was performed using the IVIS Lumina system with 
Living Image software 3.2. Thereafter, mice were sacrificed through cervical 
dislocation. Lungs were harvested, imaged separately and weighed. Images of the 
mice and the lungs were taken with a CCD camera. They were interpreted with 
equalized color bar scales, measuring the photon emission of the mice. For 
quantification of the lung signals, the images of the harvested lungs were 
analyzed. Regions of Interest (ROIs) were defined and total signals per ROI were 
calculated as photons/second/cm2 (total flux/area). Pictures were taken with an 
exposure time of 5 s and medium binning. During the experiment, mice were 
weighed every second till third day. 
Pretubulysin and chondramide B were evaluated concerning their effect on tumor 
colonization side by side in one experiment. 30 BALB/c mice were divided into 
three groups. Mice were pretreated with 0.1 mg/kg pretubulysin or 0.5 mg/kg 
chondramide B in 5% DMSO/PBS. The control group was injected with equal 
amounts of 5% DMSO/PBS. The experiment was performed with the same 
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settings as the archazolid A experiment. 
3.6.7. Effect of myxobacterial compounds on tumor growth 
Regarding the effect of myxobacterial compounds on tumor growth, archazolid A, 
pretubulysin and chondramide B were evaluated side by side in one trial. BALB/c 
mice (n = 32) were locally shaved before the injection of 2x106 4T1-Luc cells 
subcutaneously into the flank. Three days after tumor inoculation, mice were 
divided into four groups. Mice were treated with 3 mg/kg archazolid A, 0.1 mg/kg 
pretubulysin or 0.5 mg/kg chondramide B in 5% DMSO/PBS. Control mice were 
injected equal amounts of 5% DMSO/PBS. The treatment was done on day 3, 5, 
7, 10, 12, 14 and 17 after tumor inoculation. Tumors were measured every two to 
three days with a caliper, using the formula a x b2/2 with a as the widest side of 
the tumor and b the widest side vertical to a. The average tumor volumes of the 
four groups were compared over time. After the second treatment, four of the 
eight archazolid A treated mice were taken out of the experiment, because of 
edema and inflammation on the injection site. On day 18, mice were sacrificed 
through cervical dislocation. Tumors and lungs were harvested. 
In the second tumor growth experiment, 20 BALB/c mice were locally shaved and 
2x106 4T1-Luc cells were injected subcutaneously into the flank of each mouse. 
Mice were divided into two groups and treated with 3 mg/kg archazolid A in 5% 
DMSO/PBS or equal amounts of 5% DMSO/PBS. Treatment was done on day 2, 
3, 4, 5, 6, 9, 13 and 17 after tumor inoculation. Tumors were measured every two 
to three days with a caliper, using the formula a x b2/2 with a as the widest side of 
the tumor and b the widest side vertical to a. The average tumor volumes of the 
two groups were compared over time. On day 18, mice were sacrificed through 
cervical dislocation. Tumors and lungs were harvested. 
3.6.8. In vivo evaluation of polymer-melphalan conjugates 
3.6.8.1. Short-time experiment 
HuH7 cells (5x106 per mouse) were injected subcutaneously into the left shaved 
flank of ten SCID mice. On day five, mice were divided into two groups. They 
were treated i.v. 5, 7, 9, 12 and 14 days after tumor cell inoculation with the 
polymer melphalan conjugate (Conjugate 1) or the equivalent amount of 
unmodified melphalan (6 mg/kg in PBS). Tumor volumes were monitored by 
caliper measurement every second to third day, using the formula 
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a x b2/2 with a as the widest side of the tumor and b the widest side vertical to a. 
On day 16, mice were sacrificed through cervical dislocation and tumors were 
harvested. The average tumor volumes of both groups were compared over time 
and at the end of the trial (mean ± S.E.M. of five mice per group). Mice were 
weighed every second to third day. Weight of five mice per group was compared 
over time (mean ± S.E.M.). 
3.6.8.2. Long-term experiment 
SCID mice (n = 32) were injected 5x106 HuH7 cells subcutaneously into the left 
shaved flank. On day five, they were divided into four groups. They were treated 
intravenously with Conjugate 1, the equivalent amount of unmodified melphalan 
(6 mg/kg in PBS), the polymeric carrier alone or pure PBS. Injections were 
carried out on day 5, 7, 9, 12, 14 and 16 after tumor cell inoculation. Tumor 
volumes were monitored by caliper measurement using the formula a x b2/2 with 
a as the widest side of the tumor and b the widest side vertical to a. Each mouse 
was sacrificed through cervical dislocation, when its tumor reached a volume of 
1500 mm3 or the mouse lost more than 15% of its body weight. The experiment 
was terminated 120 days after tumor cell inoculation and all surviving mice were 
sacrificed. The average tumor volumes of the groups were compared over time 
(mean ± S.E.M.). As the tumors of the Conjugate 1 treated mice and of the 
melphalan treated mice were successfully treated after six injections, regrowth of 
the single tumors was compared over time. Mice were weighed at least once a 
week. Weight of eight mice per group was compared over time (mean ± S.E.M.). 
3.7. Statistical analysis 
Results are expressed as mean value ± S.E.M. Unpaired Students t-tests (one-
tailed) were performed using GraphPadPrismTM. P-values < 0.05 were considered 
as significant. 
 
 
III. Results     33 
III. RESULTS 
1. Tumor targeted siRNA delivery 
The in vitro efficacy of the folate targeted polymer FolA-PEG24-K(Stp4-C)2 in 
combination with endosomolytic Inf7-siRNA conjugate had already been 
demonstrated and is described in Dr. Christian Dohmen’s PhD thesis. The 
following studies deal with the in vivo characteristics and modification of these 
polyplexes. The experiments were performed with Daniel Edinger (PhD student, 
LMU) in NMRI nude mice and folate receptor overexpressing KB tumors. 
1.1. Functionality of the folic acid targeted carrier system 
To analyze the functionality of the folate targeted carrier system, FolA-PEG24-
K(Stp4-C)2 in combination with Cy7-labeled siRNA was injected into 
subcutaneous KB tumors. Its retention effect was compared to fluorescent labeled 
untargeted polyplex (A-PEG24-K(Stp4-C)2) and pure Cy7-labeled siRNA. 
Analysis was done using near infrared (NIR) imaging of the mice. Figure 11 
represents one mouse per group over the first 120 h after polyplex injection. 
 
 
 
 
 
 
 
 
Figure 11: Retention of polyplexes and pure siRNA in the tumor tissue. 
Targeted polyplexes (top) and untargeted polyplexes (middle), both containing 
Cy7-labeled siRNA, and pure Cy7-labeled siRNA (bottom) were injected 
intratumorally. NIR imaging was performed at different points in time till 120 h 
after polyplex/siRNA application. Pictures represent one mouse per group over 
time. The color scale (efficiency) had a minimum of 4.7e-7 and a maximum of 
1.0e-5 fluorescent photons/incident excitation photon. 
FolA-PEG24-
K(Stp4-C)2 
A-PEG24-
K(Stp4-C)2 
siRNA 
   0h        4h        24h     48h      72h      96h   120h 
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The FolA-PEG24-K(Stp4-C)2 injected mice had a strong fluorescent signal in the 
tumor, visible over 120 h. In comparison, the signal of the non-targeted 
nanoparticles disappeared after 48 h, representing a decreased retention in the 
tumor tissue. In contrast, pure siRNA was already cleared after very short time; no 
signal could be detected after 24 h. The signal caudal to the tumor (4 h after 
injection) represents targeted and untargeted polyplexes in the kidneys. Pure 
siRNA injected mice did not have any renal signal within this setting. 
In Figure 12, the fluorescence signals of all 15 mice are presented from 24 h till 
120 h after injection as total efficiency/area. The graph reveals the prolonged 
tumor retention of the folate targeted polyplex compared to the untargeted 
polyplex, and the fast clearance of free siRNA within all mice of the groups. The 
0 h values were almost identically, which can be seen in Figure 11, but are not 
presented in this graphic. 
 
 
 
 
 
 
 
Figure 12: Fluorescence signals of Cy7-labeled siRNA in tumors. After 
intratumoral injection of FolA-PEG24-K(Stp4-C)2 or A-PEG24-K(Stp4-C)2 
combined with Cy7-labeled siRNA or pure labeled siRNA, fluorescence signals 
of the tumors were determined as total efficiency/area. Represented is the mean 
± S.E.M. of five mice per group. 
 
1.2. Intratumoral gene silencing after local polyplex application 
The NIR images proved the increased tumor retention of the targeted polyplexes. 
The intracellular uptake and the activity of the siRNA could not been 
demonstrated within this experiment. For evaluation of the gene silencing effect, 
targeted polyplexes containing Inf7-siEG5 were injected intratumorally. EG5 is a 
protein, which is active in spindle formation during mitosis. Silencing of the EG5 
gene leads to a mitotic arrest of the affected cells and thus to mitotic figures, so 
called “asters”. These formations are detectable by means of microscopy. 
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Targeted polyplexes containing Inf7-siCtrl were injected as negative control. 
Figure 13 exemplifies the increased number of mitotic figures in tumors treated 
with FolA-PEG24-K(Stp4-C)2 containing Inf7-siEG5, compared to tumors treated 
with Inf7-siCtrl including polyplexes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Intratumoral EG5 mRNA knockdown by targeted siRNA. FolA-
PEG24-K(Stp4-C)2 polyplexes containing Inf7-siCtrl (left side) or Inf7-siEG5 
(right side) were injected intratumorally. 24 h after application, tumors were 
harvested and stained with haematoxylin and eosin. Right pictures represent more 
mitotic figures than left pictures. 
FolA-PEG24-K(Stp4-C)2 + Inf7-siCtrl FolA-PEG24-K(Stp4-C)2 + Inf7-siEG5 
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1.3. Biodistribution of the initial polymer 
In the following experiments, polyplexes were injected intravenously to evaluate 
the biodistribution and clearance of siRNA in combination with the targeted 
polymer. FolA-PEG24-K(Stp4-C)2 containing Cy7-labeled siRNA was applicated 
into the  tail veins of the mice and its distribution in the body was observed 
through NIR imaging. Polyplexes had a similar distribution in all mice (n = 3); 
pictures of one mouse are shown in Figure 14.  
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Biodistribution of i.v. injected FolA-PEG24-K(Stp4-C)2 bound 
siRNA. FolA-PEG24-K(Stp4-C)2 combined with Cy7-labeled siRNA was injected 
intravenously into tumor bearing mice. NIR imaging was performed at several 
points in time (15 min, 1 h, 4 h, 24 h). Images represent the polyplex 
biodistribution in one mouse in ventral (top) and dorsal (bottom) position over 
time. The color scale had a minimum of 3.7e-7 and a maximum of 2.47e-6 
fluorescent photons/incident excitation photon. 
 
After 15 min, the strongest fluorescence signal was observed in the kidneys and in 
the bladder of the animals. The tumor tissue (nape) was the only fluoresce tissue 
beside the genitourinary system. 4 h after injection, most of the polyplexes were 
cleared. In spite of systemical application, polyplexes did not accumulate in any 
other tissue than the tumor and were completely cleared by the kidneys. Mice 
were clinically monitored during the experiment and did not show any medical 
condition. 
FolA-PEG24- 
K(Stp4-C)2 + 
Cy7-siRNA 
  0.25h            1h               4h              24h 
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1.4. Biodistribution of modified polymers 
1.4.1. Polymers with extended PEG spacer 
FolA-PEG24-K(Stp4-C)2/siRNA polyplexes have a hydrodynamic radius of only 
2.8 nm, causing a relatively fast renal clearance. In the following experimental 
setups, the size of the polymers was enlarged (Table 1), using additional precise 
PEG24 molecules with the objective of obtaining a prolonged circulation time of 
the siRNA and to increase the EPR effect. 
Table 1: Hydrodynamic radius [nm] of the siRNA polyplexes. Hydrodynamic 
radius of polyplexes, using Cy5-labeled Inf7-siRNA at N/P 16. Determined by Dr. 
Christian Dohmen and Christina Troiber (LMU) through fluorescent correlation 
spectroscopy. 
 
Polymer rh [nm] 
FolA-PEG24-K(Stp4-C)2 2.8 ± 0.1 
FolA-PEG48-K(Stp4-C)2 3.2 ± 0.1 
FolA-PEG72-K(Stp4-C)2 4.4 ± 0.1 
A-PEG120-K(Stp4-C)2 5.8 ± 0.2 
A-PEG192-K(Stp4-C)2 25.4 ± 0.9 
 
Precise prolonged polyplexes, containing FolA-PEG48-K(Stp4-C)2 and FolA-
PEG72-K(Stp4-C)2 combined with Cy7-labeled siRNA, were injected 
intravenously into mice and NIR images were taken. Figure 15 represents one 
mouse per group. Compared to FolA-PEG24-K(Stp4-C)2, no difference was seen in 
the distribution and clearance of the modified polymers. 
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Figure 15: Biodistribution of i.v. injected, polymeric
 
bound siRNA. Cy7-
labeled siRNA was injected systemically in combination with FolA-PEG48-
K(Stp4-C)2 (left) or FolA-PEG72-K(Stp4-C)2 (right) into tumor bearing mice. NIR 
imaging was performed in ventral (upper panel) and dorsal (lower panel) position 
over the following 24 h. The color scale had a minimum of 3.7e-7 and a 
maximum of 2.47e-6 fluorescent photons/incident excitation photon. 
 
In the next step, polymers were synthesized with five (A-PEG120-K(Stp4-C)2) and 
eight (A-PEG192-K(Stp4-C)2) monodisperse PEG24 chains. These polymers did not 
include folic acid, as the focus of this experiment was put on the impact on 
circulation time and not on tumor targeting. Nanoparticles, now reaching a 
hydrodynamic radius of 5.8 nm and 25.4 nm, were analyzed in their distribution 
properties as before. Figure 16 represents one mouse per group. The measurement 
was stopped after 1 h due to the weak signals at later points in time in previous 
trials. Both modified polyplexes still had a fast renal clearance, but showed a 
better tissue distribution in the first 30 min compared to the initial polyplexes. The 
polyplex with 5 PEG spacers had the most extensive distribution at all points in 
time, especially after 15 min and 30 min. 
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Figure 16: Biodistribution of i.v. injected siRNA linked to untargeted 5 PEG 
and 8 PEG containing polyplexes. Cy7-labeled siRNA was combined with A-
PEG120-K(Stp4-C)2 (middle) or A-PEG192-K(Stp4-C)2 (right) and injected 
intravenously into tumor free mice. As control, the initial polyplex containing 
FolA-PEG24-K(Stp4-C)2 was injected intravenously (left). NIR imaging was 
performed in ventral (upper panel) and dorsal position (lower panel) 15 min, 
30 min and 60 min after application. The color scale had a minimum of 1.0e-6 and 
a maximum of 9.6e-6 fluorescent photons/incident excitation photon. 
 
1.4.2. Polymers with hydrophobic modifications 
As the enlargement of the polymers by additional PEG spacers was limited, 
polymers were synthesized containing hydrophobic domains like tyrosines, 
caprylic acids or stearic acids. The hydrophobic modification with tyrosine did not 
influence particle size, whereas caprylic acids and stearic acids increased the 
polyplex size (Table 2).  
Table 2: Hydrodynamic radius [nm] of polyplexes with hydrophobic 
modified polymers. Hydrodynamic radius of polyplexes, using Cy5-labeled Inf7-
siRNA at N/P 16. Determined by Dr. Christian Dohmen and Christina Troiber 
(LMU) through fluorescent correlation spectroscopy. 
Polymer rh [nm] 
C-Y3-Stp4-K(Stp4-Y3-C)-PEG24-FolA 2.8  
C-K(K-CapA2)-Stp4-K(Stp4-K(K-CapA2)-C)-PEG24-FolA 17 
C-K(K-SteA2)-Stp4-K(Stp4-K(K-SteA2)-C)-PEG24-FolA 160 
 
The newly synthesized polymers including Cy7-labeled siRNA were injected 
intravenously and NIR imaging was performed. Figure 17 represents one mouse 
per group. The modification with tyrosine or alternatively caprylic acid induced a 
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liver accumulation and a delayed renal clearance (represented in a later kidney 
and bladder signal). Addition of stearic acid resulted in lung accumulation, 
leading to the death of the mouse during anesthesia. 
 
 
 
 
 
 
 
 
 
Figure 17: Biodistribution of i.v. injected siRNA in combination with 
hydrophobic modified polymers. Initial polymers were modified with additional 
tyrosines (Y3), caprylic acids (CapA) or stearic acids (SteA). Biodistribution is 
shown in ventral (left side) and dorsal (right side) position of one mouse per group 
over 24 h. The color scale had a minimum of 2.66e-7 and a maximum of 2.0e-6 
fluorescent photons/incident excitation photon. 
1.5. Stability of the polyplexes 
Especially after i.v. injection, stability is essential for the polyplex efficacy. As the 
fluorescent stain Cy7 was covalently bound to the siRNA, a positive fluorescence 
signal only implicated the presence and distribution of siRNA, without saying 
anything about its complexation with the polymers. For evaluation of the stability, 
polyplexes with 1 PEG chain and with 8 PEG chains were analyzed in a gel shift 
assay (Figure 18). Using the polymer FolA-PEG24-K(Stp4-C)2, siRNA remained 
complexed with an increase of polyplex stability with high N/P ratios. In 
comparison, A-PEG192-K(Stp4-C)2 complexed with siRNA was less stable within 
every analyzed N/P ratio so that free siRNA was detectable. 
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Figure 18: Gel electrophoresis of the polyplexes. Polyplexes containing 500 ng 
of siRNA in 20 µL HBG and loading buffer were placed into the sample pockets 
of an agarose gel in different N/P ratios. Free siRNA was used as control. 
Electrophoresis was performed at 120 V for 40 min. Experiment was performed 
by Christina Troiber (PhD student, LMU). 
 
To investigate the polyplex stability after systemic application into the mice, urine 
samples were taken 4 h after intravenous injection of FolA-PEG24-K(Stp4-C)2 
complexed with siRNA, FolA-PEG72-K(Stp4-C)2 complexed with siRNA or free 
siRNA and analyzed in an agarose gel with (+) or without (-) preincubation with 
the particle disruptive agents TCEP and heparin (Figure 19). 
 
 
 
 
 
 
 
 
 
Figure 19: Gel electrophoresis of urine samples after i.v. polyplex injection. 
Polyplexes with 1 PEG or 3 PEG chains and free siRNA were injected 
intravenously into mice. 4 h after application, urine samples were taken and 
analyzed by gel electrophoresis. Free siRNA was used as control (C). Samples 
were analyzed without further treatment (-) or after incubation with TCEP and 
heparin (+). Experiment was performed by Dr. Christian Dohmen (LMU). 
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Without additional TCEP and heparin, polyplexes remained stable, as there was 
no free siRNA detectable in the gel. 
1.6. Molecular biological activity of systemically injected polyplexes 
Prolongation of FolA-PEG24-K(Stp4-C)2 with 5 PEG24 spacers increased the 
distribution of the polyplex. However, most of the polyplex modifications did not 
achieve tremendous changes in the circulation time of the particles. Therefore, it 
was investigated if FolA-PEG24-K(Stp4-C)2 causes gene silencing in the tumor 
tissue after i.v. injection, in spite of the weak fluorescence signal. For this 
purpose, the polymer was combined with Inf7-siEG5 and injected i.v. As controls, 
Inf7-siEG5 was injected in combination with the untargeted polymer A-PEG24-
K(Stp4-C)2 and the targeted carrier was injected, containing Inf7-siCtrl. Figure 20 
shows DAPI stained tumor sections 24 h after the treatment. Both polyplexes 
containing Inf7-siEG5 led to mitotic figures in the tumor tissue, whereby the 
targeted polyplex caused about threefold more mitotic figures than the untargeted 
polyplex. In the control sections, no mitotic figures were detectable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Gene silencing effect of i.v. injected, polymeric bound siRNA. 
DAPI stained tumor sections 24 h after application of FolA-PEG24-K(Stp4-C)2 
containing Inf7-siEG5 (left), A-PEG24-K(Stp4-C)2 containing Inf7-siEG5 (middle) 
or FolA-PEG24-K(Stp4-C)2 containing Inf7-siCtrl (right). Arrows highlight mitotic 
figures. 
FolA-PEG24- 
K(Stp4-C)2 + 
Inf7-siEG5 
FolA-PEG24- 
K(Stp4-C)2 + 
Inf7-siCtrl 
A-PEG24- 
K(Stp4-C)2 + 
Inf7-siEG5 
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2. Efficiency of myxobacterial products in murine tumor 
models 
In the following experiments, the efficiency of the myxobacterial compounds 
archazolid A, pretubulysin and chondramide B was analyzed in vivo concerning 
tumor cell colonization and tumor growth. These experiments were performed 
together with Rebekka Kubisch (PhD student, LMU). Previous cell culture assays 
had already shown the inhibitory effect of the compounds on cell proliferation and 
migration (DFG network Vollmar/Müller FOR 1406 "Exploiting the Potential of 
Natural Compounds: Myxobacteria as Source for Leads, Tools, and Therapeutics 
in Cancer Research”). 
2.1. Effects on tumor cell colonization 
In the first experiment, we evaluated the V-ATPase inhibitor archazolid A. 
BALB/c mice (n = 20) were divided into two groups, one control group and one 
treatment group, and luciferase expressing syngeneic 4T1 breast tumor cells were 
injected intravenously. 24 h and 4 h before tumor inoculation, the treatment group 
had been medicated with 1 mg/kg archazolid A. Figure 21 represents the luciferin 
signals of the 4T1-Luc tumors at the end of the trial (day eight). 
III. Results     44 
 
 
 
Figure 21: Bioluminescence images. A) Pictures of mice developing 4T1-Luc 
tumors (without pretreatment). The upper panel shows dorsoventral, the lower 
panel ventrodorsal images of the control mice. B) Pictures of the archazolid 
pretreated mice. The upper panel shows dorsoventral, the lower panel 
ventrodorsal images of the pretreated mice. C) Images of the harvested lungs. 
Upper panel shows the tumor burden of the lungs of the group without 
pretreatment, the lower panel the lungs of the pretreated group. Each lung was 
pictured from dorsal and ventral side. 
B) 
A) 
C) 
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All mice of the group without archazolid medication had a thoracic luminescence 
signal, displaying the lung tumor burden of each mouse. Nine of ten control mice 
had a very strong signal, showing the development of a high number of tumor 
cells. The strongest signals were seen, when mice lay in dorsal position. The 
archazolid A treated mice had much weaker signals than the control mice. Within 
these settings, two of these animals even had no luciferin signal at all. For the 
definite localization of the signals, lungs were harvested and imaged separately 
(Figure 21 C). Two pictures (dorsal and ventral side) were taken per organ. The 
results comply with the images of the animals, as the control lungs had much 
higher luciferin signals than the lungs of the archazolid A pretreated mice. During 
the trial, all mice were in good general condition and did not show any weight loss 
(Figure 22). 
 
 
 
 
 
 
 
 
 
Figure 22: Weight of mice. Weight of the archazolid A pretreated and of the 
untreated (control) mice, starting with tumor cell inoculation (day 0), ending with 
euthanasia (day 8). Mean ± S.E.M. of ten mice per group. 
 
For quantification of the tumor burden, the bioluminescence signals of the lungs 
were calculated as photons/second/cm2 (total flux/area). The mean ± S.E.M. is 
represented in Figure 23 A. The average luminescence signal in the pretreated 
group was significant lower than in the control group. After imaging, lungs were 
weighed. Figure 23 B represents the mean weight ± S.E.M. of ten lungs per group. 
Lungs of the control group were significant heavier compared to the pretreated 
group, caused by their higher tumor burden. 
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  A)        B) 
Figure 23: Quantification of the tumor burden in the lungs. A) The luciferin 
signal of the harvested lungs was calculated as photons/second/cm2 (total 
flux/area). Bars represent the mean ± S.E.M. (***p<0.0001 (t-test)). B) Lungs 
were weighed. Bars represent the mean ± S.E.M. of ten lungs per group 
(***p<0.0001 (t-test)). 
 
Subsequent to the archazolid experiment, the effect of pretubulysin (0.1 mg/kg) 
and chondramide B (0.5 mg/kg) on tumor cell colonization was analyzed with 
analogous experimental setups. Figure 24 presents the tumor burden of the mice, 
revealed through the bioluminescence signals of the 4T1-Luc tumor cells. 
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Figure 24: Bioluminescence images. A) Pictures of the mice without 
pretreatment (control). B) Pictures of the pretubulysin pretreated mice. C) Pictures 
of the chondramide B pretreated mice. The upper panel of each graphic shows the 
mice in ventral, the lower panel in dorsal position. 
 
The control mice (Figure 24 A) had the strongest luciferin signal. Ten of ten mice 
had developed visible lung tumors like in the pretubulysin treated group 
(Figure 24 B). One of the chondramide B treated mice (Figure 24 C) did not have 
a luciferin signal within these settings. Nevertheless, in average, the pretubulysin 
group had optically the smallest tumor burden in the lungs, followed by the 
chondramide B treated mice. The difference in signal strength between the 
C) 
B) 
A) 
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chondramide B pretreated and the control mice was visually assumable, but not 
absolute clear. After euthanasia of the animals, lungs were harvested and imaged 
separately (Figure 25). The results represent the findings of the previous pictures, 
indicating a higher anti-colonization effect of pretubulysin compared to 
chondramide B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Bioluminescence images of the harvested lungs. The upper panel 
shows the lungs of the control mice without pretreatment, the middle panel the 
lungs of the pretubulysin pretreated mice and the lower panel the lungs of the 
chondramide B pretreated mice. Each lung was pictured from dorsal and ventral 
side. 
 
To quantify the luminescence, signals of the lungs were again calculated as total 
flux/area (Figure 26 A). This analysis proved the optical impression of the 
pictures. Pretubulysin and chondramide B treated mice had a significant lower 
tumor burden than the control mice, whereby pretubulysin had a higher efficacy 
than chondramide B. Figure 26 B demonstrates the weight of the lungs. 
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Figure 26: Quantification of the tumor burden in the lungs. A) The luciferin 
signal of the harvested lungs was calculated as photons/second/cm2 (total 
flux/area). Bars represent the mean ± S.E.M. (***p<0.0001 (t-test)). B) Lungs 
were weighed. Bars represent the mean ± S.E.M. of ten lungs per group 
(***p<0.0001 (t-test)). 
While pretubulysin had a significant effect using this evaluation method, 
chondramide B did not reduce the weight of the lungs significantly. Compared to 
archazolid, pretubulysin had a weaker anti-colonization efficacy and chondramide 
B even less. Mice were in good general condition during the experiment and none 
of them lost remarkable weight. Figure 27 shows the average weight of the groups 
over time. 
 
 
 
 
 
 
 
Figure 27: Weight of mice. Weight of the pretubulysin and chondramide B 
pretreated and of the untreated (control) mice, starting with tumor cell inoculation 
(day 0), ending with euthanasia (day 8). Represented is the mean ± S.E.M. per 
group over time. 
2.2. Influence on tumor growth 
Besides the impact of the three compounds on cell colonization, we were also 
interested in their effect on hampering tumor growth. Therefore, we investigated 
archazolid A, pretubulysin and chondramide B in a subcutaneous tumor model 
A) B) 
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with 4T1-Luc cells. Tumor bearing mice were treated intravenously with the 
myxobacterial compounds or PBS for 7 times between day 3 and 17 after tumor 
inoculation. Archazolid A was injected within a concentration of 3 mg/kg, 
whereas the concentrations of pretubulysin and chondramide B remained the same 
as in the colonization experiment (0.1 mg/kg and 0.5 mg/kg). Four of eight 
animals of the archazolid treated group had to be taken out of the experiment after 
the second application, as the injection sites became oedematous and 
inflammatory. In a growth curve (Figure 28 A), groups show a similar increase in 
tumor volume. The only compound, which could hamper tumor growth at least 
temporarily within this trial, was archazolid A (Figure 28 B). 
 
Figure 28: Tumor volume over time. BALB/c mice bearing subcutaneous 4T1-
Luc tumors upon seven intravenous treatments (day 3, 5, 7, 10, 12, 14 and 17) 
with PBS (control), 3 mg/kg archazolid A, 0.1 mg/kg pretubulysin or 0.5 mg/kg 
chondramide B. A) Average tumor volumes of the four groups (mean ± S.E.M.) 
over time. B) Average tumor volumes of the archazolid A treated group, 
compared to the control group (mean ± S.E.M. per group, *p<0.05 (t-test)). 
 
As the effect of tumor growth retardation by archazolid A was not significant at 
the end, a second trial with modified settings was carried out. This time, 
archazolid A was the only evaluated compound and already injected the first time 
on day two. Treatment was continued every 24 h for several days and repeated at 
the end of the trial. In total, the compound was injected eight times instead of 
seven times as in the previous trial. Figure 29 shows the growth curve of the 
tumors. Again, archazolid A reduced tumor growth only slightly. In this 
experiment, the difference was not significant at any points in time. 
 
 
* 
* 
* 
A) B) 
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Figure 29: Tumor volume over time. BALB/c mice bearing subcutaneous 4T1-
Luc tumors upon eight intravenous treatments (day 2, 3, 4, 5, 6, 9, 13 and 17) with 
PBS (control) or 3 mg/kg archazolid A. Average tumor volumes (mean ± S.E.M. 
per group) are presented over time. 
3. Efficacy of polymer-melphalan formulations 
To evaluate the improvement of the therapeutic effect of melphalan due to its 
polymeric immobilization, the three novel polymeric melphalan formulations 
were analyzed concerning their impact on cell viability and proliferation. Basing 
on the in vitro results, a short-time in vivo experiment was performed, comparing 
Conjugate 1 with the equivalent amounts of unmodified melphalan. In a mainly 
analogous, but more extensive animal experiment, these two treatment groups 
were compared to two control groups over a longer period of time. Dr. Anita 
Bogomilova synthesized the polyphosphoesters and the melphalan formulations. 
3.1. Effect on cell viability and proliferation 
To analyze the antitumoral activity of the three synthesized melphalan 
formulations in vitro, both metabolic activity of cells by MTT assay, representing 
enzymatic protein activity of tumor cells, and proliferation activity, representing 
the amount of tumor cell chromatin, was determined. The polymer-bound 
formulations were compared with equivalent doses of unmodified melphalan. 
Untreated and pure polymer treated cells were used as control. 
On HuH7 cells, pure melphalan had a higher potency in the MTT assay 
(Figure 30 A, C, E) than polymer bound melphalan at the medium dose of 
50 µg/mL. However, at a concentration of 100 µg/mL, the immobilization of 
melphalan led to a strong antitumoral activity, comparable to pure melphalan. In 
total, the efficacy of Conjugate 1 was a bit weaker in comparison to Complex 2 
and Complex 3, but within the highest concentration (100 µg/mL) Conjugate 1 
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also had a strong effect on hampering cell metabolism. 
In the proliferation assay on HuH7 cells (Figure 30 B, D, F), the melphalan 
formulations reached an equal or almost equal reduction of tumor DNA as 
unmodified melphalan. Within the highest concentration, cell proliferation was 
decreased to about 20% of the control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Treatment of HuH7 cell cultures with indicated concentrations (µg/mL 
melphalan equivalents) of unmodified melphalan, Conjugate 1, Complex 2, 
Complex 3, or 200 µg/mL free polymer. After 3 days culture under standard 
conditions, MTT assays for detection of cell metabolic activity (A, C, E) and 
H33342 dye staining for determining cell proliferation (B, D, F) were performed. 
A) B) 
D) C) 
E) F) 
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In the next experiments, SKBR3 cells were used. The MTT assay 
(Figure 31 A, C, E) showed similar results as before. Both, the melphalan 
formulations and pure melphalan had a comparable efficacy on cell viability, 
especially at a concentration of 100 µg/mL. Overall, the treatment was more 
effective than in HuH7 cells, reaching a reduction of metabolic activity of more 
than 90% with the highest melphalan concentration.  
In the proliferation assay on SKBR3 cells (Figure 31 B, D, F), immobilized 
melphalan was as effective as pure melphalan. The treatment led to a very low 
amount of tumor cell chromatin (under 10% of control cells). 
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Figure 31. Treatment of SKBR3 cell cultures with indicated concentrations 
(µg/mL melphalan equivalents) of unmodified melphalan or Conjugate 1, 
Complex 2, Complex 3, or 200 µg/mL free polymer. After 3 days culture under 
standard conditions, MTT assays for detection of cell metabolic activity (A, C, E) 
and H33342 dye staining for determining cell proliferation (B, D, F) were 
performed. 
 
In the following experiments, the antitumoral effects of the polymeric 
formulations were evaluated on U87MG cells. This cell line did not response as 
strong as HuH7 and SKBR3 cells to the treatment. However, the melphalan 
conjugate and the complexes reduced the metabolic activity (Figure 32 A, C, E) 
E) F) 
D) 
B) A) 
C) 
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and cell proliferation (Figure 32 B, D, F) comparable to pure melphalan. 
Pure polymer (without incorporated melphalan) had no cytotoxic effect on the 
cells in all in vitro experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Treatment of U87MG cell cultures with indicated concentrations 
(µg/mL melphalan equivalents) of unmodified melphalan or the three polymer-
incorporated forms, or 200 µg/mL free polymer. After 3 days culture under 
standard conditions, MTT assays for detection of cell metabolic activity (A, C, E) 
and H33342 dye staining for determining cell proliferation (B, D, F) were 
performed. 
C) D) 
E) F) 
A) B) 
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3.2. In vivo studies 
Conjugate 1, which - due to covalent linkage - presents the most stable form of 
incorporation, and nevertheless displays high antitumoral activity in vitro, was 
selected for further in vivo evaluation in a subcutaneous HuH7 model in SCID 
mice. 
3.2.1. Short-time experiment 
A preliminary in vivo experiment was performed to determine the efficacy and 
toxicity of the conjugate. Mice were divided into two groups; one was treated with 
unmodified melphalan (6 mg/kg), one with the polymer-melphalan conjugate 
(equal dose of melphalan). HuH7 cells were injected subcutaneously and mice 
were treated intravenously 5 times from day 5 till day 14. The experiment was 
terminated on day 16 after measurement of the tumor volumes. Starting with the 
second treatment, the tumor growth in the Conjugate 1 treated group was 
hampered compared to the melphalan treated group (Figure 33 A). From day nine 
on, tumor growth stagnated in the Conjugate 1 treated group and tumors even 
decreased, whereas the tumors of the melphalan treated group showed a 
constantly increasing volume. From day twelve (fourth treatment) on, the mean 
tumor volume of the conjugate group was significant smaller than the tumor 
volume of the melphalan group (Figure 33 A and B). Beside the tumor specific 
effects, no obvious signs of toxicity, like weight loss of mice, were detected 
(Figure 33 C). 
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Figure 33: Tumor volume and weight of mice. SCID mice (n = 10) bearing 
subcutaneous HuH7 tumors upon five intravenous treatments (day 5, 7, 9, 12, 14) 
with pure melphalan or melphalan Conjugate 1 at a dosage of 6 mg/kg melphalan 
equivalent. A) Tumor volume over time and B) at the end of the experiment (day 
16). Values represent the mean ± S.E.M. of five mice per group. ***p<0.0001 (t-
test) C) Average weight of mice per group as mean ± S.E.M. 
3.2.2. Long-term experiment 
Basing on the previous in vivo results, a more comprehensive experiment 
including two control groups, was performed. Mice (n = 32) were divided into 
four groups and treated intravenously for six times (day 5, 7, 9, 12, 14, 16) with 
unmodified melphalan, conjugated melphalan, polymeric carrier alone or PBS. 
Tumor growth was monitored by caliper measurement. In this experiment, each 
tumor of the melphalan and Conjugate 1 treated group showed a complete 
regression after 27 days (Figure 34 A). In the same time, tumors of both control 
groups grew rapidly and mice had to be sacrificed between day 16 and 40. From 
day 42 on, regrowth of 4 melphalan treated tumors and 1 conjugate treated tumor 
was observed (Figure 34 A and B). 
* 
*** 
*** 
B) A) 
C) 
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Figure 34: Tumor growth over time. SCID mice (8 per group) bearing 
subcutaneous HuH7 tumors upon 6 intravenous treatments (day 5, 7, 9, 12, 14, 16) 
with PBS, free polymer, pure melphalan or Conjugate 1 at a dosage of 6 mg/kg 
melphalan equivalent. A) Tumor volumes over time (measured until mice had to 
be sacrificed due to tumor burden). Number of tumor-developing mice at the end 
of the experiment (day 120) is indicated in brackets. B) Tumor regrowth 
(volumes) in the individual (4/8) melphalan (M1-M4) or (1/8) Conjugate 1 (C1) 
treated mice (average data shown in A). 
 
Mice were weighed during the entire experiment to monitor their general 
condition. In the first 25 days, unspecific weight loss was detected, occurring in 
all groups (Figure 35 A). After this initial phase, mice gained weight again. For a 
better presentation, only the weight of both treatment groups is shown over the 
whole time (Figure 35 B). The experiment was terminated on day 120, when all 
heretofore survived animals, having a good general condition, were sacrificed. 
 
 
 
 
 
Figure 35: Weight of mice over time. A) Weight of mice of all groups in the 
first 25 days. Mean of eight mice per group ± S.E.M. B) Weight of mice, treated 
with pure melphalan or Conjugate 1, over the experimental time. Mean of eight 
mice per group ± S.E.M. 
 
A) B) 
A) B) 
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IV. DISCUSSION 
1. Tumor targeted siRNA delivery 
1.1. Mode of action of intratumoral injected polyplexes 
In the first in vivo experiments, polyplexes were injected locally into subcutanous 
folate receptor overexpressing KB tumors. Within this experimental setup, we 
demonstrated that the polymer under investigation, FolA-PEG24-K(Stp4-C)2, had a 
longer retention time in the tumor tissue than the untargeted polymer, A-PEG24-
K(Stp4-C)2 (Figure 12). As both polyplexes were identical apart from the folic 
acid ligand, this proves that folate enabled a tumor specific targeting through 
folate receptor binding.  
Folate receptors are overexpressed in many tumor types,139, 140 but have a limited 
normal tissue distribution141 and thus, are a suitable and commonly used cell 
surface protein for targeted cancer therapy. Folic acid has a high affinity to folate 
receptors and its binding leads to receptor-mediated endocytosis, which 
circumvents cell penetration problems of charge neutral polyplexes.142 Therefore, 
it was assumed that FolA-PEG24-K(Stp4-C)2 was internalized through receptor 
binding, but this could not be proven within the NIR imaging (Figure 11).  
The taken pictures only demonstrated the increased tumor retention of the 
polyplexes due to folic acid as targeting ligand, whereas no information about the 
polyplex internalization and the siRNA efficiency was given. Therefore, the gene 
silencing effect of the polyplexes was investigated by knocking down the mitotic 
kinosin EG5 encoding mRNA. The resulting number of mitotic figures 
demonstrated that the polyplexes did not remain in the extracellular space after 
application, but overcame all critical bottlenecks of local nucleic acid delivery 
(Figure 13). Due to the folic acid, FolA-PEG24-K(Stp4-C)2 was able to attach to 
the tumor cells and was internalized. The next hurdle in the delivery process is the 
endosomal escape. To overcome this obstacle, the siRNA was conjugated to Inf7, 
an endosomolytic peptide based on the sequence of the amino-terminus of 
influenza virus hemagglutinin subunit 2 (HA-2). This lytic peptide was developed 
by Plank et al. in 1994.43 Inf7 is only lytic at an acidic pH of 5.5, which prevents 
extracellular toxicity due to lytic activity. This is an advantage over pH-unspecific 
lytic peptides, like mellitin.143 Additionally, endosomal escape due to Inf7 is 
IV. Discussion       60 
independent of the amount of polyplexes per endosome and is therefore more 
effective compared to the proton sponge effect. All these overcome obstacles 
represent big challenges in nucleic acid therapy144, 145 and thus, these results are 
very promising for further siRNA delivery.  
1.2. Biodistribution of systemic injected polyplexes 
In most cases, a local application of cancer therapeutics is not possible. Therefore, 
a systemic injection is necessary to reach the tumor tissue. Thus, polyplexes were 
injected intravenously for further investigations. This method bears several 
additional bottlenecks in nucleic acid delivery. The nucleic acid needs to be 
protected from unwanted interactions with other cells. If the siRNA is not bound 
effectively, it can be degraded in the blood circulation, or polyplexes can 
accumulate in organs, typically the liver, spleen and lung. As a result, the nucleic 
acid loses its efficacy and strong toxic side effects through untargeted gene 
silencing may occur. Therefore, polyplexes were synthesized contained 
polyethylene glycol (PEG), an often used hydrophilic molecule for surface 
shielding of pharmaceuticals.36, 146, 147 
In the following experiments, the initial polyplex was applicated intravenously. 
The injection of FolA-PEG24-K(Stp4-C)2 complexed Cy7-labeled siRNA caused 
fluorescent signals in the tumor tissue, and the kidneys and bladder due to its renal 
clearance (Figure 14). No other tissue was targeted by the polyplexes, indicating 
that the pegylation led to a charge neutralization of the polyplexes, preventing 
unwanted interactions with untargeted organs. The good tolerability of systemic 
polyplex injection was proven by the absence of weight loss or reduced general 
condition. Additionally, the polyplexes were completely cleared, causing no 
residues in the body. 
1.3. Modification of the polymers 
The investigated polyplexes fulfilled all necessary prerequisites for the delivery 
process, but had a short circulation time. However, besides active targeting, 
passive tumor targeting is another method to increase the uptake of nucleic acids 
in tumor cells. This method underlies the so called EPR effect,148 as described 
before. Nanoparticles may pass the leaky tumor endothel and accumulate in the 
tumor tissue due to its pure lymphatic drainage. A long circulation time can 
increase this effect. 
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To gain larger particles and thus, prolong the circulation time of the polyplexes 
due to a slower renal clearance, 1 PEG to 8 PEG spacers were added to the 
polycationic backbone. FolA-PEG48-K(Stp4-C)2 and FolA-PEG72-K(Stp4-C)2 had 
similar distribution characteristics like the initial polymer (Figure 15). This could 
be explained by their small radius of 3.2 nm and 4.4 nm (Table 1), resulting in a 
fast renal filtration.149 In the following, polyplexes with 5 PEG and 8 PEG 
spacers, reaching a radius of 5.8 nm and 25.4 nm, were evaluated after systemic 
injection. 
A-PEG120-K(Stp4-C)2 including 5 PEG24 achieved a wider distribution in the 
body, improving the diffusion of the initial polyplex. This effect was caused by its 
increased size, leading to a delayed renal clearance. A-PEG120-K(Stp4-C)2 even 
had a better distribution than A-PEG192-K(Stp4-C)2 (Figure 16). 
Further analysis by gel electrophoresis showed that this was probably caused by 
the increased instability of the 8 PEG chains containing polyplex (Figure 18). It is 
known, that relatively long PEG chains can destabilize pegylated polyplexes, 
especially under in vivo conditions.150 With the distribution refinement of 5 PEG 
chains containing polyplexes, the amount of siRNA reaching the tumor tissue 
might be increased. On the other hand, the instability of A-PEG192-K(Stp4-C)2 
showed the limitation of the polyplex modification and enlargement by additional 
pegylation. Hence, polyplexes were altered using hydrophobic domains. 
By short hydrophobic modification with tyrosines, no change of polymer size 
occurred, whereas additional caprylic or stearic acids led to particles with a 
hydrodynamic radius of 17 nm or 160 nm, respectively. Tyrosines and caprylic 
acids prolonged the half life of the polyplexes, which was visible in the delayed 
bladder and kidney signal of the mice (Figure 17). Unfortunately, this was not due 
to a better circulation but only due to liver accumulation of the particles. In this 
case, the pegylation could not shield the hydrophobic character of the new 
polyplexes. Modification with stearic acids dramatically increased the particle size 
and led to an accumulation in the lung of the mouse with lethal toxic side effect. 
1.4. Stability of the polyplexes 
The fluorescence signals in the biodistribution assays represented the diffusion of 
Cy7-labeled siRNA. Its stable binding to the polymers was assumed due to the 
targeted tumor accumulation, but had to be proven in another experiment. For the 
definite prove, gel electrophoresis of the polyplexes with 1 PEG, 3 PEG and 
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8 PEG chains was carried out. In the first gel shift (Figure 18), the initial polymer 
turned out to form more stable polyplexes, when compared with A-PEG192-
K(Stp4-C). Basing on these results, the in vivo stability of FolA-PEG24-K(Stp4-C)2 
and FolA-PEG72-K(Stp4-C)2 was evaluated by a gel electrophoresis of urine 
samples after i.v. polyplex injection (Figure 19). The fluorescence signal seen in 
the in vivo trials was produced by Cy7-linked, still polymer bound siRNA, as the 
polyplexes FolA-PEG24-K(Stp4-C) and FolA-PEG72-K(Stp4-C) remained stable. 
Thus, the pegylation could successfully reduce interactions with blood 
components and degradation by the reticuloendothelial system. 
The hydrophobic modified polyplexes also remained stable in the blood 
circulation, obvious through the occurring fluorescent signal in the liver. Pure 
siRNA would not accumulate in the liver, but be quickly cleared by the kidneys. 
1.5. Molecular biological effect after systemic polyplex application 
FolA-PEG24-K(Stp4-C)2 siRNA complexes had a good gene silencing effect after 
local application. However, its distribution characteristics after systemic injection 
indicated a small molecular biological effect due to a weak tumor fluorescence 
signal. Prolongation of the circulation time, which could increase the amount of 
delivered siRNA in the tumor, could be reached due to additional PEG spacers but 
was limited. Therefore it was important to evaluate the gene silencing efficacy of 
FolA-PEG24-K(Stp4-C)2 bound Inf7-siRNA after systemic application. 
The targeted polyplex was compared with the untargeted polyplex, both 
containing Inf7-siEG5. As a second control, the targeted polymer was injected in 
combination with Inf7-siCtrl. Both polyplexes containing Inf7-siEG5 led to 
mitotic figures in the tumor tissue through gene silencing, whereby the targeted 
polyplex caused an about threefold higher number of asters than the untargeted 
polyplex (Figure 20). This experiment showed that even though the amount of 
nanoparticles in the tumor after 24 h did not cause a visible fluorescence signal, 
enough polyplexes reached their target area for specific gene silencing. 
IV. Discussion       63 
2. Myxobacterial compounds 
The three myxobacterial compounds archazolid, pretubulysin and chondramide 
were analyzed regarding their effect on tumor growth and tumor metastasis in 
vivo. For this purpose, murine 4T1 breast tumor cells were used. These cells have 
a good growth rate and can be inoculated into BALB/c mice, as they originate 
from and therefore are syngeneic with this mouse strain. To track tumor cell 
dissemination and tumor growth by bioluminescence imaging, we injected stable 
luciferase expressing 4T1 cells (4T1-Luc). 
As none of the compounds had been evaluated concerning metastasis in vivo 
before, we decided to use simplified setups for this analysis. Thus, we did not 
inject cells subcutaneously or orthotopically to spontaneously metastasize, but we 
injected the cells intravenously, mimicking the process of vascular migration. 
Within these setups, the cells migrated out of the blood circulation and colonized 
a new tissue, which was almost without exception the lung. The drugs were 
injected before tumor cell inoculation, to imitate the situation of a treated primary 
tumor with the aim of preventing its metastasis.  
The colonization experiments were terminated eight days after the injection of 
4T1-Luc cells, as this time period was on the one hand long enough to evaluate 
the compounds through bioluminescence imaging and on the other hand short 
enough to maintain a good general condition of the mice. None of the animals 
showed any health problems in consequence of their pulmonary tumor burden.  
In the subcutaneous tumor growth experiments, we terminated the trials within 
18 days, as the 4T1-Luc tumors became necrotic after this time. Although the 
tumor volumes did not reach a critical size until these points in time, we stopped 
the experiments, as tumor necrosis would affect the bioluminescence signals and 
might lead to painful conditions for the animals. 
2.1. Influence of archazolid on tumor growth and colonization 
V-ATPases play an important role in tumor cell migration and metastasis. They 
regulate the microenvironment of tumors by acidifying the extracellular space. 
This enables tumor cells to be invasive and to migrate into other tissues.151 
In 2005, Lu et al. had already demonstrated that the knockdown of ATP6L, a 
subunit of the V-ATPase complex, through siRNA suppresses the growth and 
metastasis of human hepatocellular carcinoma.152 These findings strengthened the 
IV. Discussion       64 
assumption that archazolid can reduce tumor metastasis in vivo, caused by the 
inhibition of V-ATPases. 
Indeed, two systemic injections of 1 mg archazolid A per kg body weight led to a 
reduced migration of 4T1-Luc cells out of the circulation into the lung and 
therefore, to a significant lower tumor burden, compared to the control group 
(Figure 21 and 23). 
As archazolid had never been evaluated in vivo before, these first colonization 
results have been important and are very promising for further investigations of 
archazolid.  
Previous cell culture studies had not only shown that archazolid hampers cell 
migration, but had also demonstrated that archazolid is highly effective in 
reducing cell proliferation of different mammalian cell lines in vitro.71, 79 
Therefore, we evaluated its effect on reducing tumor growth in vivo as well. 
Unfortunately, multiple intravenous injections of 3 mg/kg archazolid A could only 
slightly decrease the growth of established subcutaneous 4T1-Luc tumors 
(Figure 28). There was no significant difference between the average tumor 
volume of the treated and untreated group at the end of the trial.  
After gaining these results, we changed the experimental settings for a second 
tumor growth experiment. In this trial, we started the treatment earlier and 
shortened the intervals between each application at the beginning of the 
experiment. Overall, we injected archazolid once more (eight times), compared to 
the first settings. However, these alterations did not improve the antitumor 
efficacy of archazolid (Figure 29).  
Ohta et al. has already published in vivo data of bafilomycin and concanamycin, 
two V-ATPase inhibitors that are in vitro as potent as archazolid. They found out 
that the daily subcutaneous injection of 1 mg/kg of these compounds led to a 
significant decrease in the growth of subcutaneous tumors after 21 days.153  
In our tumor growth experiment, we injected the threefold amount of archazolid 
intravenously, but only for seven or eight times. The problem was that almost all 
of the subcutaneous 4T1-Luc tumors became necrotic after that time period. 
Therefore, we had to terminate the experiments on day 18 after tumor inoculation 
to guarantee a proper evaluation of the results and a good general condition of the 
mice. At that point in time, the tumors had been smaller than 600 mm3 in average. 
As subcutaneous tumors are allowed to grow until they reach a volume of 
1500 mm3 in our experimental setups, they usually could have been monitored for 
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further days. Besides the problem of tumor necrosis, 4T1-Luc tumors had 
originally a poor blood supply. As a consequence, the experimental settings for 
further tumor growth experiments have to be improved and new tumor models 
have to be evaluated. 
Using a higher archazolid concentration in vivo might be problematic, as it was 
already shown that multiple applications of bafilomycin and concanamycin in 
lower doses can lead to an insulin deficiency and therefore to a later risk of 
diabetes.154 Additionally, when we injected a concentration of 3 mg/kg archazolid, 
we realized edema and inflammation at the injection side. Only minimal 
paravenous amounts of archazolid induced these side effects. It is known that 
chemotherapeutics can produce tissue necrosis and perivenous extravasation in 
different manifestations.155, 156 When this problem occurred in the first tumor 
growth trial, we had to take four animals out of the experiment. Afterwards, there 
were no difficulties concerning this issue, as we injected archazolid even more 
carefully and thus prevented further complications. Beside this, no other toxicity 
occurred. 
In summary, a clear effect on preventing colonization, but less effect on tumor 
growth was demonstrated. 
2.2. Influence of pretubulysin on tumor growth and colonization 
Microtubules targeting compounds gain more and more attention in cancer 
therapy and there are already several natural compounds like taxanes or vinca 
alkaloids part of tumor therapy157 or in clinical trials.158, 159 
In our experiments, we analyzed the in vivo efficacy of pretubulysin, a structural 
simplified precursor of the tubulin polymerization inhibitor tubulysin. To our 
knowledge, the collaborative work of our group and the Vollmar group, in which 
the anti-angiogenesis effect of pretubulysin was evaluated in a subcutaneous 
HuH7 tumor model (published by Rath et al.), was the first successful application 
of pretubulysin in vivo.84  
In our colonization experiment, the pretreatment of the mice with 0.1 mg 
pretubulysin per kg body weight led to a significant reduction of colonized 4T1-
Luc cells in the lungs, compared to the untreated group (Figure 24 – 26). 
Regarding the effect of pretubulysin on tumor cell migration, there had only been 
in vitro49 but no in vivo data published before. Thus, these results prove for the 
first time that pretubulysin can hamper tumor cell colonization in vivo. This effect 
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is probably caused by the inhibition of tubulin polymerization, as microtubules 
play a crucial role in cell migration. 
Concerning tumor growth, multiple i.v. injections of 0.1 mg/kg pretubulysin had 
no therapeutic effect within our experimental setups (Figure 28), whereas Rath et 
al. could already show that multiple intravenous treatments with 0.1 mg/kg 
pretubulysin did significantly reduce HuH7 tumor growth.84 The HuH7 
experiments proved that pretubulysin not only hampered tumor growth but also 
tumor angiogenesis. These findings explain the better efficacy of pretubulysin in 
HuH7 tumors compared to 4T1 tumors, as hepatocellular carcinomas such as 
HuH7 tumors, are the most vascularized solid tumors. Thus, they are strongly 
affected by anti-angiogenetic drugs. Moreover, there is a higher amount of 
pretubulysin reaching HuH7 tumors because of their good blood supply. 
Tubulysin A has a very comparable in vitro efficacy as pretubulysin and has 
already been investigated in different in vivo experiments before.160 It turned out 
to be toxic in a concentration of 0.1 mg/kg body weight, which was below its 
therapeutic dose. To reduce its toxicity, tubulysin A was bound to a polymeric 
backbone. The resulting complex led to a significant tumor growth delay of colon 
carcinoma, when injected intravenously three times a week in a concentration of 
3 mg/kg tubulysin A. Furthermore, a semisynthetic analog of tubulysin B was 
already used to create a folate conjugate. This conjugate overcame the dose-
limiting toxicities of tubulysin B and led to a significant reduction of tumor 
growth.161 
Taking together these findings, 0.1 mg/kg pretubulysin reduced the growth of well 
vascularized HuH7 tumors, whereas the same concentration of the closely related 
compound tubulysin A did not impair the growth of less vascularized colon 
carcinoma. Therefore, the cause for the insufficient impact of pretubulysin in our 
growth experiments might have been the low amount of pretubulysin, reaching the 
poorly vascularized tumor tissue.  
It was encouraging that multiple intravenous injections of 0.1 mg/kg pretubulysin 
did not cause any obvious side effects. However, as pretubulysin can probably be 
compared to tubulysin A, a higher dose might be toxic for the animals. 
Summarizing, pretubulysin could reduce tumor colonization in the lungs at a low 
concentration. This concentration was however not high enough to impair solid 
tumor growth in our experiments. Pretubulysin might be comparable to tubulysin 
A and tubulysin B and therefore, a good candidate for targeted tumor delivery. 
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Polymeric immobilization of pretubulysin could possibly reduce the toxicity of 
higher pretubulysin doses and might target the compound to the tumor site. This 
could enhance its effectiveness and enable the treatment of rarely vascularized 
tumors, like the 4T1-Luc tumors, with a higher dose. 
2.3. Influence of chondramide on tumor growth and colonization 
Chondramide was the third myxobacterial product, we evaluated in animal 
experiments. In comparison to archazolid and pretubulysin, this actin 
polymerization promoter had the lowest antitumor efficacy in vivo. Nevertheless, 
chondramide still reduced the colonization of 4T1-Luc cells in the lungs of 
BALB/c mice significantly (Figure 24 - 26). Comparable to archazolid and 
pretubulysin, it had a weaker effect in the subcutaneous tumor model and could 
not affect tumor growth (Figure 28). 
Chondramide had shown to impair the growth of different tumor cells in vitro 
before. As chondramide is structurally very closely related to jasplakinolide, their 
cytotoxic efficacy was compared and found out to be very similar.69, 88, 162 
Chondramide itself had not been tested in animal experiments before, but the in 
vivo information about jasplakinolides gave us a hint for choosing the 
chondramide dose for our experiment. 1.5 mg/kg jasplakinolide injected i.p. for 
multiple times had been shown to reduce tumor growth and metastasis of Lewis 
lung carcinoma in mice.90 We decided to use a lower concentration of 0.5 mg/kg 
chondramide, but to inject it intravenously, as we did with archazolid and 
pretubulysin. 
Fortunately, this dose did not cause any visible toxicity in the mice, but at the 
same time reduced the colonization of 4T1-Luc cells significantly. Actin is 
necessary for cell migration163 and intervention in its polymerization process leads 
to dramatic migration defects. This might explain the reduction of tumor 
colonization in our animal experiments. 
In the tumor growth experiment however, chondramide could not influence the 
proliferation of 4T1-Luc cells in a concentration of 0.5 mg/kg, although actin 
plays an important role in cell proliferation. 
As mentioned before, the growth of solid 4T1-Luc tumors was already harder to 
influence comparing to tumor cell colonization with archazolid and pretubulysin. 
Apparently, the compounds reach the tumor cells in a higher amount, when cells 
are injected intravenously like the compounds themselves. Subcutaneous growing 
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tumors are difficult to target, especially when they are not well vascularized like 
the 4T1-Luc tumors. 
At the moment, there is only little information about the characteristics of 
chondramide in vivo. Therefore, it will be difficult to improve this model within a 
short time. As chondramide was not toxic at all, the next step might be to increase 
the injection dose. Additionally, using another cell line that forms better 
vascularized tumors without becoming necrotic, could be successful. 
3. Polymer linked melphalan 
3.1. In vitro efficacy of polymer-melphalan formulations 
In MTT and proliferation assays on different cell lines (HuH7, SKBR3 and 
U87MG), the three novel polymeric melphalan formulations had a comparable 
effect on cell viability and cell proliferation as equivalent amounts of pure 
melphalan (Figures 30 – 32). Low-molecular-weight drugs enter cells rapidly by 
crossing the plasma membrane, whereas conjugated drugs usually are internalized 
slower through endocytosis and have a delayed drug release within endosomes or 
lysosomes.164, 165 As a result, conjugates are generally less cytotoxic in vitro than 
their free counterparts.120 Therefore, the achievement of an equal cytostatic effect 
of the polyphosphoester bound melphalan compared to the pure melphalan was a 
promising result concerning further in vivo experiments. 
An often occurring problem in polymer-drug conjugation is the toxicity of the 
synthesized polymers. Thus, the efficiency of the phosphoester polymers was 
tested without melphalan incorporation, too. The results of MTT and proliferation 
assays showed that pure polymer did neither influence the metabolic activity, nor 
the proliferation of the cells (Figures 30 – 32). This finding is well consistent with 
the previously published high biocompatibility of phosphoester polymers. It 
proves that the evaluated polymers did not cause any cell toxicity and were not the 
reason for the cytotoxicity of polymer linked melphalan. Additionally, the 
polymer increased the water solubility of melphalan, leading to a simplified 
preparation of the injection solution. Gaining these promising in vitro results, we 
planned further evaluations in animal experiments. 
For in vivo trials, one cell line and one polymeric system, evaluated in the in vitro 
assays, were chosen. Although SKBR3 cells were the most sensitive cell line, the 
also responsive HuH7 cells were used in the following animal experiments. 
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Investigations in previous trials had shown that this well established cell line has a 
better growth rate and blood supply than SKBR3 or U87MG cells. Amongst the 
polymeric formulations, melphalan was covalently bond to a polymer 
(poly(oxyethylene H-phosphonate)) only in one case (by P-O or P-N bonds), 
forming Conjugate 1. In Complex 2, the negatively charged phosphodiester 
polymer poly(hydroxyoxyethylene phosphate) was complexed to positively 
charged melphalan through ionic bonds, in Complex 3 the neutral phosphotriester 
(poly(methyloxyethylene phosphate) binds melphalan through hydrogen bonding. 
The in vitro efficacy of the three systems had been very comparable. Conjugate 1 
was the only formulation with a covalent bond, which is more stable than the 
ionic and hydrogen bonds of the two complexes. It was remarkable that 
Conjugate 1 had almost equal cytotoxic effects as Complex 2 and Complex 3, 
despite melphalan was covalently immobilized on the polymer. In vivo, this tight 
bonding protects melphalan from dissociation in the blood circulation. For this 
reason, Conjugate 1 was chosen for animal experiments. 
3.2. In vivo efficacy of the polymer-melphalan conjugate 
In the first in vivo experiment, polymer-melphalan conjugate (Conjugate 1) 
treated mice developed significant smaller tumors than mice treated with the equal 
amount of pure melphalan (Figure 33 A and B). After a first delay of tumor 
growth, the tumor volumes stagnated during the treatment with the polymer 
conjugated melphalan. Tumors treated with an equivalent dose of pure melphalan 
grew significantly faster. Thus, this trial showed that polymeric conjugation of 
melphalan to the synthesized poly(oxyethylene H-phosphonate) led to a strong 
improvement of its therapeutic efficacy in vivo.  
The enhanced therapeutic effect of Conjugate 1 treated mice occurred only short 
time after the first injection and was presumably caused by the EPR effect.96 By 
conjugating melphalan to the polyphosphoester, the low-molecular-weight drug 
achieved a macromolecular size. This probably enabled the drug to passively 
target the tumor and to accumulate in the tumor tissue. Thus, a higher amount of 
melphalan might have reached the tumor compared to the pure drug, increasing 
the efficacy of the conjugate. Therefore, the novel polymeric analogue could have 
overcome the lack of tumor selectivity, a major limitation of most conventional 
anticancer chemotherapeutics.166 
Beside the tumor toxicity, no other side effects like weight loss (Figure 33 C) or a 
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reduced general condition occurred, indicating the tolerability of the conjugate 
treatment. Usually, the passive targeting to the tumor site and the decreased body 
dissemination of conjugated cytostatic drugs reduces toxic side effects. As the 
dose of melphalan was relatively low and did not cause any visible toxicity under 
the experimental conditions, this effect could not be shown in this experimental 
setup. 
In the following more comprehensive animal experiment, the two treatment 
groups were compared to a PBS and a pure polymer injected group. This was 
done to analyze the in vivo toxicity of the pure polymer and to compare the results 
to a control group. In this experiment, all tumors treated with polymer-melphalan 
conjugate or pure melphalan showed a complete growth regression within the first 
27 days (Figure 34 A). When mice were treated on day five for the first time, 
tumors had an average volume of 50 mm3 and thus, they were 20 mm3 smaller 
than tumors in the first in vivo trial at that time. This could be the reason for the 
stronger therapeutic response of these tumors compared to the tumors of the first 
experiment. Because of the nice complete regression of the treated tumors, no 
difference was seen in antitumor efficacy between melphalan and the polymer-
melphalan conjugate at this occasion. 
However, as tumor relapse plays an important role in cancer therapy,167 mice were 
monitored for tumor regrowth over 120 days. Animals of both control groups 
showed a rapid tumor growth, leading to their early euthanasia between day 16 
and 40. In the following days, four of eight tumors of the melphalan treated group 
and only one of eight tumors of the conjugate treated group regrew (Figure 34 B). 
This could have had different causes. 
The decreased tumor regrowth in the conjugate treated mice could be caused by 
an increased initial cytostatic efficacy of the conjugate. Through polymeric 
conjugation, a higher amount of melphalan could have reached the tumor site 
because of the EPR effect. In the tumor tissue, the enhanced drug concentration 
could then affect more tumor cells compared to the pure melphalan. As a result, 
fewer tumors were able to regrow. 
The EPR effect not only leads to passive targeting for short-term tumor delivery, 
but it induces a prolonged drug retention, up to several weeks or longer.105 
Polymers are able to release a drug controlled over time. Thus, polyphosphoester 
conjugation could have prolonged the therapeutic effect of melphalan up to more 
than 100 days. Therefore, melphalan conjugates could enable a more convenient 
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therapy for patients, prolonging the intervals between cytostatic treatments. This 
controlled release of anticancer drugs is already successfully utilized within the 
application of polymer conjugates in prostate cancer therapy.168, 169 
Another hope in the use of polymers is the possible circumvention of drug 
resistance. One cause of multidrug resistance is the efflux of drugs out of the cells 
through different ABC transporters, for example P-glycoprotein.170-172 Miyamoto 
et al. described the hampered efflux of polymer conjugated drugs compared to 
free drugs, which was probably caused by a reduced binding of the polymeric 
drug to P-glycoprotein. Macromolecular drugs do not seem to interact with the 
ABC transporter system.173, 174 In case the tumor contains already multidrug-
resistant tumor cell clones, this might be an additional reason for the reduced 
amount of tumor regrowth after six treatments with the conjugated drug (one of 
eight tumors), compared to the higher regrowth rate after pure melphalan 
injections (four of eight tumors). 
In the first 25 days of the experiment, the mice lost some weight (Figure 35 A). 
As most of the mice were affected, whether belonging to the treatment groups or 
to the control groups, this was an unspecific side effect, being reducible to the 
application distress. None of these mice lost more than 10% of its body weight. 
After this initial time period, mice started to gain weight again (Figure 35 B). 
Neither mice of the treatment groups nor of the pure polymer injected group 
showed any signs of reduced general condition. The polymer itself was non-toxic 
for the animals. 
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V. SUMMARY 
Cancer is a leading cause of death worldwide. Although several common 
treatment options exist, there is an urgent need for improved tumor therapeutics. 
Therefore, we evaluated three innovative anticancer approaches in vivo. These 
were newly synthesized siRNA polyplexes, novel myxobacterial anticancer 
compounds, and innovative polymeric melphalan formulations. 
We evaluated the in vivo characteristics of polymeric bound siRNA. We could 
demonstrate that the polymer FolA-PEG24-K(Stp4-C)2 is an efficient carrier for 
targeting siRNA to the folate receptor expressing tumor tissue of mice. Moreover, 
the siRNA was able to enter tumor cells and led to specific gene silencing. After 
systemic injection, the polyplexes did neither cause any toxic side effects nor 
accumulate in any healthy organ. With only 6 nm average diameter, polyplexes 
were very small, resulting in fast removal from blood circulation by renal 
clearance. Addition of larger PEG spacers to the initial polyplex led to an 
increased polyplex size. As a result, the renal clearance was decreased, and 
polyplex distribution in the body was optimized. These results show that the in 
vivo hurdles of siRNA delivery can be overcome by binding siRNA to the precise 
and multifunctional polymers. 
Natural compounds have broad therapeutic effects, and are basis for the 
production of various anticancer drugs. Myxobacterial products often target cell 
structures which are rarely targeted by other metabolites, and they exert novel 
modes of action. Therefore, they are of particular importance for the development 
of new anticancer drugs. In this thesis, we evaluated three novel myxobacterial 
compounds in vivo. Within our experimental settings, we could demonstrate for 
the first time that archazolid, pretubulysin and chondramide can impair the 
migration and colonization of breast cancer cells in mice. Concerning their impact 
on tumor growth reduction, the compounds have promising characteristics, but the 
experimental setups need further improvement. 
Cytostatic drugs, like melphalan play an important role in cancer therapy, but bear 
problems, such as a low therapeutic efficacy and strong toxic side effects. 
Immobilization of chemotherapeutics on polymers is an interesting option to 
reduce their toxicity and enhance their efficacy, mainly by passive tumor 
targeting. We evaluated three innovative polymer-melphalan formulations in cell 
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viability and proliferation assays. The covalent conjugate of poly(oxyethylene H-
phosphonate) with melphalan was additionally investigated in vivo. This 
polymeric immobilization of melphalan led to an improved therapeutic effect 
compared to the pure cytostatic drug, as the growth and regrowth of HuH7 tumors 
could be hampered effectively. 
In conclusion, this thesis deals with the in vivo evaluation of innovative cancer 
therapeutics, which were successfully investigated in murine tumor models. The 
results with the experimental agents, based on siRNA, polymers or biogenic 
drugs, are encouraging starting points for further anticancer research. 
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VI. ZUSAMMENFASSUNG 
Krebserkrankungen gehören zu den weltweit häufigsten Todesursachen. Dies 
verdeutlicht, dass es trotz der vielfältigen bestehenden Behandlungsmethoden 
einer Verbesserung in der Krebstherapie bedarf. Aus diesem Grund haben wir drei 
innovative Therapieansätze in Tumormausmodellen analysiert. Dazu zählen neu 
synthetisierte siRNA Polyplexe, myxobakterielle Naturstoffe und innovative auf 
Polymeren basierende Melphalan Formulierungen. 
Mit der tierexperimentellen Evaluierung von an Polymere gebundener siRNA 
konnten wir zeigen, dass FolA-PEG24-K(Stp4-C)2 ein effizienter Vektor ist, um 
siRNA zu Folsäurerezeptor exprimierenden Tumorzellen zu transportieren. 
Darüber hinaus konnte die an das Polymer gebundene siRNA in die Tumorzellen 
eindringen und die Expression der entsprechenden Gene hemmen. Die Polyplexe 
akkumulierten weder in Organen noch führte ihre systemische Injektion zu 
toxischen Nebenwirkungen. Sie wurden schnell über die Nieren ausgeschieden, da 
sie einen Durchmesser von nur 6 nm haben. Die Vergrößerung der Polyplexe über 
weitere PEG Einheiten erhöhte ihre Halbwertszeit und führte zu einer optimierten 
Verteilung im Körper. Die Schwierigkeiten des gezielten in vivo siRNA 
Transportes konnten durch den Einsatz der Polymere überwunden werden. 
Naturstoffe haben ein breites Wirkungsspektrum und spielen eine große Rolle in 
der Entwicklung von Zytostatika. Myxobakterielle Stoffwechselprodukte besitzen 
oft neuartige Wirkungsmechanismen, da sie an Zellstrukturen angreifen, die das 
Ziel von nur wenigen anderen Naturstoffen sind. Aus diesem Grund sind sie von 
großem Interesse für die Entwicklung neuer Krebstherapeutika. Wir haben die 
Eigenschaften von drei myxobakteriellen Sekundärmetaboliten in vivo untersucht. 
Unsere Ergebnisse zeigen zum ersten Mal, dass Archazolid, Pretubulysin und 
Chrondramid die Migration von murinen Tumorzellen in der Maus hemmen. Die 
analysierten Naturstoffe sind zudem vielversprechend bezüglich ihrer Wirkung 
auf das Wachstum solider Tumore. Um diesen Effekt in vivo zu verdeutlichen, 
müssen die Versuchsbedingungen jedoch weiter optimiert werden.  
Chemotherapeutika, wie zum Beispiel Melphalan, werden häufig in der 
Krebstherapie angewendet. Ihr Einsatz ist jedoch mit starken Nebenwirkungen 
und einer nur bedingten Wirksamkeit verbunden. Durch die Bindung an Polymere 
können Zytostatika gezielter ins Tumorgewebe transportiert werden. Dies 
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verstärkt ihre Wirksamkeit und reduziert gleichzeitig ihre Toxizität. Wir haben 
Melphalan an drei innovative Polymere gekoppelt und die Wirksamkeit dieser 
Formulierungen in vitro getestet. Zusätzlich wurde die Wirkung des aus 
Melphalan und poly(Oxyethylene H-phosphonat) hergestellten Konjugates in vivo 
untersucht. In Wachstumsversuchen mit HuH7 Tumoren zeigte das Konjugat eine 
stärkere zytostatische Wirkung als pures Melphalan. Im Hinblick auf die 
Entstehung von Tumorrezidiven war das Konjugat ebenfalls wirksamer als pures 
Melphalan. 
Zusammenfassend haben wir uns in dieser Arbeit mit der in vivo Evaluierung 
innovativer Krebstherapeutika in Tumormausmodellen beschäftigt. Die erzielten 
Ergebnisse mit den auf siRNA, Polymeren oder Naturstoffen basierenden 
Therapeutika stellen einen vielversprechenden Ausgangspunkt für weitere 
Forschungsarbeiten dar. 
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VIII. APPENDIX 
1. Abbreviations 
CapA Caprylic acid 
CCD Charge-coupled Device 
DAPI 4',6-diamidino-2-phenylindole 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsRNA Double-stranded ribonucleic acid 
e.g. exempli gratia (for example) 
EDTA Ethylenediaminetetraacetic acid 
EG5 Eglin 5, or KSP, Kinesin spindle protein 
EPR effect Enhanced permeability and retention effect 
FCS Fluorescence correlation spectroscopy 
FCS Fetal calf serum 
FolA Folic acid 
HA-2 Hemagglutinin subunit 2 
HBG Hepes buffered glucose 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic 
acid) 
i.p. Intraperitoneal(ly) 
i.v. Intravenous(ly) 
LCA Leber congenital amaurosis 
LPEI Linear polyethylenimine 
Luc Luciferin 
MDR Multidrug resistance 
mRNA Messenger ribonucleic acid 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
N/P Polymer nitrogen to nucleic acid phosphate ratio 
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 NIR Near infrared   
PBS Phosphate buffered saline 
pDNA Plasmid deoxyribonucleic acid 
PEG Polyethylene glycol 
PEG24 Polyethylene glycol with exactly 24 monomers  
( = “1 PEG”) 
P-glycoprotein Permeability glycoprotein 
rh Hydrodynamic radius 
RISC Ribonucleic acid induced silencing complex 
RNA Ribonucleic acid 
RNAi Ribonucleic acid interference 
ROI Region of Interest 
S.E.M. Standard Error of the Mean 
SCID Severe combined immunodeficiency 
siRNA Small interfering ribonucleic acid 
SteA Stearic acid 
Stp Succinoyl-tetraethylenpentamine 
TBE-buffer Tris-Boric acid-EDTA-buffer 
TCEP Tris(2-carboxyethyl)phosphine 
V-ATPase Vacuolar-type H+-ATPase 
w/v Weight per volume 
Y3 Tyrosin-Tyrosin-Tyrosin (Tyrosin trimer) 
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